




## CONTENTS

---

Frontispiece— <i>Jean D. Wilson</i>	xiv
<b>PERSPECTIVES, Joseph F. Hoffman, Editor</b>	
A Double Life: Academic Physician and Androgen Physiologist, <i>Jean D. Wilson</i>	1
<b>CARDIOVASCULAR PHYSIOLOGY, Jeffrey Robbins, Section Editor</b>	
Lipid Receptors in Cardiovascular Development, <i>Nick Osborne and Didier Y.R. Stainier</i>	23
Cardiac Hypertrophy: The Good, the Bad, and the Ugly, <i>N. Frey and E.N. Olson</i>	45
Stress-Activated Cytokines and the Heart: From Adaptation to Maladaptation, <i>Douglas L. Mann</i>	81
<b>CELL PHYSIOLOGY, Paul De Weer, Section Editor</b>	
Cell Biology of Acid Secretion by the Parietal Cell, <i>Xuebiao Yao and John G. Forte</i>	103
Permeation and Selectivity in Calcium Channels, <i>William A. Sather and Edwin W. McCleskey</i>	133
Processive and Nonprocessive Models of Kinesin Movement, <i>Sharyn A. Endow and Douglas S. Barker</i>	161
<b>COMPARATIVE PHYSIOLOGY, George N. Somero, Section Editor</b>	
Origin and Consequences of Mitochondrial Variation in Vertebrate Muscle, <i>Christopher D. Moyes and David A. Hood</i>	177
Functional Genomics and the Comparative Physiology of Hypoxia, <i>Frank L. Powell</i>	203
Application of Microarray Technology in Environmental and Comparative Physiology, <i>Andrew Y. Gracey and Andrew R. Cossins</i>	231
<b>ENDOCRINOLOGY, Bert W. O'Malley, Section Editor</b>	
Nuclear Receptors and the Control of Metabolism, <i>Gordon A. Francis, Elisabeth Fayard, Frédéric Picard, and Johan Auwerx</i>	261

Insulin Receptor Knockout Mice, <i>Tadahiro Kitamura, C. Ronald Kahn, and Domenico Accili</i>	313
The Physiology of Cellular Liporegulation, <i>Roger H. Unger</i>	333
<b>GASTROINTESTINAL PHYSIOLOGY, John Williams, Section Editor</b>	
The Gastric Biology of <i>Helicobacter pylori</i> , <i>George Sachs, David L. Weeks, Klaus Melchers, and David R. Scott</i>	349
Physiology of Gastric Enterochromaffin-Like Cells, <i>Christian Prinz, Robert Zanner, and Manfred Gratzl</i>	371
Insights into the Regulation of Gastric Acid Secretion Through Analysis of Genetically Engineered Mice, <i>Linda C. Samuelson and Karen L. Hinkle</i>	383
<b>NEUROPHYSIOLOGY, Richard Aldrich, Section Editor</b>	
In Vivo NMR Studies of the Glutamate Neurotransmitter Flux and Neuroenergetics: Implications for Brain Function, <i>Douglas L. Rothman, Kevin L. Behar, Fahmeed Hyder, and Robert G. Shulman</i>	401
Transducing Touch in <i>Caenorhabditis elegans</i> , <i>Miriam B. Goodman and Erich M. Schwarz</i>	429
Hyperpolarization-Activated Cation Currents: From Molecules to Physiological Function, <i>Richard B. Robinson and Steven A. Siegelbaum</i>	453
<b>RENAL AND ELECTROLYTE PHYSIOLOGY, Steven C. Hebert, Section Editor</b>	
Macula Densa Cell Signaling, <i>P. Darwin Bell, Jean Yves Lapointe, and János Peti-Peterdi</i>	481
Paracrine Factors in Tubuloglomerular Feedback: Adenosine, ATP, and Nitric Oxide, <i>Jürgen Schnermann and David Z. Levine</i>	501
Regulation of Na/Pi Transporter in the Proximal Tubule, <i>Heini Murer, Nati Hernando, Ian Forster, and Jürg Biber</i>	531
Mammalian Urea Transporters, <i>Jeff M. Sands</i>	543
Terminal Differentiation of Intercalated Cells: The Role of Hensen, <i>Qais Al-Awqati</i>	567
<b>RESPIRATORY PHYSIOLOGY, Carole R. Mendelson, Section Editor</b>	
Current Status of Gene Therapy for Inherited Lung Diseases, <i>Ryan R. Driskell and John F. Engelhardt</i>	585
The Role of Exogenous Surfactant in the Treatment of Acute Lung Injury, <i>James F. Lewis and Ruud Veldhuizen</i>	613
Second Messenger Pathways in Pulmonary Host Defense, <i>Martha M. Monick and Gary W. Hunninghake</i>	643

Alveolar Type I Cells: Molecular Phenotype and Development, <i>Mary C. Williams</i>	669
<b>SPECIAL TOPIC: LIPID RECEPTOR PROCESSES, Donald W. Hilgemann,</b> <i>Special Topic Editor</i>	
Getting Ready for the Decade of the Lipids, <i>Donald W. Hilgemann</i>	697
Aminophospholipid Asymmetry: A Matter of Life and Death, <i>Krishnakumar Balasubramanian and Alan J. Schroit</i>	701
Regulation of TRP Channels Via Lipid Second Messengers, <i>Roger C. Hardie</i>	735
Phosphoinositide Regulation of the Actin Cytoskeleton, <i>Helen L. Yin and Paul A. Janmey</i>	761
Dynamics of Phosphoinositides in Membrane Retrieval and Insertion, <i>Michael P. Czech</i>	791
<b>SPECIAL TOPIC: MEMBRANE PROTEIN STRUCTURE, H. Ronald Kaback,</b> <i>Special Topic Editor</i>	
Structure and Mechanism of Na,K-ATPase: Functional Sites and Their Interactions, <i>Peter L. Jorgensen, Kjell O. Håkansson,</i> <i>and Steven J. Karlish</i>	817
G Protein-Coupled Receptor Rhodopsin: A Prospectus, <i>Slawomir Filipek, Ronald E. Stenkamp, David C. Teller, and</i> <i>Krzysztof Palczewski</i>	851
<b>INDEXES</b>	
Subject Index	881
Cumulative Index of Contributing Authors, Volumes 61–65	921
Cumulative Index of Chapter Titles, Volumes 61–65	925
<b>ERRATA</b>	
An online log of corrections to <i>Annual Review of Physiology</i> chapters may be found at <a href="http://physiol.annualreviews.org/errata.shtml">http://physiol.annualreviews.org/errata.shtml</a>	



# SUBJECT INDEX

## A

- AAVSI gene
  - lung gene therapy and, 590
- Acclimation
  - microarray technology and, 231-51
- Acetylcholine
  - acid secretion by parietal cell and, 103-23
  - gastric acid secretion in genetically engineered mice and, 383-96
- Acetyl CoA carboxylase (ACC)
  - liporegulation and, 335-37
- Acheta domestica*
  - transducing touch in *Caenorhabditis elegans* and, 433
- Acidosis
  - hensin and terminal differentiation, 567-80
- Acid resistance/tolerance
  - gastric biology of *Helicobacter pylori* and, 349-50, 353-64
- Acid secretion
  - gastric
    - enterochromaffin-like cells and, 371-77
    - genetically engineered mice and
      - acetylcholine pathway, 390-91
      - ADA promoter, 395
      - chromogranin A promoter, 394
      - conclusions, 395-96
      - ECL cells, 394
      - forestomach, 395
      - G cells, 394, 395
      - gastric mucosal hypertrophy, 390-91
      - gastrin, 394-95
      - gastrin pathway, 387-88, 390
      - histamine pathway, 388-90
      - introduction, 383-87
      - loss-of-function, 387-88
      - overexpression, 388
      - parietal cells, 391-94
      - somatostatin pathway, 391
      - transgenes, 393-95
  - parietal cells and, 371-77
  - actin, 118-22
    - actin-based
      - cytoskeleton, 118-22
    - activation, 109-11
    - adaptor proteins, 115
    - cAMP, 106-9
    - cholinergic pathways, 109-11
    - clathrin coat proteins, 115
    - duodenal peptides, 112
    - dynamain, 116
    - EGF, 111-12
    - ezrin, 120-22
    - fusion reaction, 122
    - H,K-ATPase, 112-18
    - introduction, 103-4
    - miscellaneous cellular proteins, 121-22
    - myosin Vb, 116-17
    - neural peptides, 112
    - perspectives, 123
    - PKA, 106-9
    - protein phosphorylation, 106-9
    - Rab proteins, 114-15
    - signal transduction
      - underlying gastric acid secretion, 106-12
    - SNARE proteins, 113-14
    - structural basis, 104-6
    - TGF $\alpha$ , 111-12
    - trafficking, 112-18
- Acquired lipodystrophy
  - liporegulation and, 333
- Acrp30 protein
  - liporegulation and, 338
- $\alpha$ -Actinin
  - phosphoinositide regulation of actin cytoskeleton and, 775-76
- Actins
  - acid secretion by parietal cell and, 118-22
  - hensin and terminal differentiation, 569, 574
  - lung gene therapy and, 596
  - phosphoinositide regulation of actin cytoskeleton and, 761-80
- Activation
  - acid secretion by parietal cell and, 103-23
  - G protein-coupled receptor rhodopsin and, 867-69
  - hensin and terminal differentiation, 579
  - hyperpolarization-activated cation currents and, 453-72
  - lung gene therapy and, 599
  - NMR of glutamate neurotransmitter flux and neuroenergetics, 410-11
  - phosphoinositide regulation of actin

- cytoskeleton and, 767–68, 772
- stress-activated cytokines and the heart, 81–95
- TRP channel regulation via lipid second messengers and, 749–50
- Active cation transport proteins
- Na,K-ATPase structure and mechanism, 817–41
- Active urea transport
- mammalian urea transporters and, 543, 555–56
- Acute acid resistance
- gastric biology of *Helicobacter pylori* and, 354–63
- Acute respiratory distress syndrome (ARDS)
- acute lung injury (ALI) and surfactant therapy for, 613–32
- Acyl-CoA synthetase
- nuclear receptors in metabolism and, 269, 274
- A-cytoplasmic domains
- Na,K-ATPase structure and mechanism, 817–41
- Adaptive immunity
- second messenger pathways in pulmonary host defense and, 657
- Adaptive remodeling
- mitochondrial variation in vertebrate muscle and, 177, 187–89
- Adaptive response
- stress-activated cytokines and the heart, 81, 83–88
- functional genomics and comparative physiology of hypoxia, 203–24
- microarray technology and, 231–51
- nuclear receptors in metabolism and, 261
- Adaptor proteins
- acid secretion by parietal cell and, 115
- ADE ciliated sensory neurons transducing touch in *Caenorhabditis elegans* and, 435
- Adeno-associated virus (AAV)
- recombinant lung gene therapy and, 585, 590–92, 596–604
- Adenosine
- macula densa cell signaling and, 493–95
- paracrine factors in tubuloglomerular response and, 501–14
- Adenosine 1 receptors (A1AR)
- paracrine factors in tubuloglomerular response and, 501, 505–6
- Adenosine deaminase (ADA)
- promoter gastric acid secretion in genetically engineered mice and, 395
- Adenosine triphosphate (ATP)
- gastric biology of *Helicobacter pylori* and, 354–55
- macula densa cell signaling and, 493–95
- mitochondrial variation in vertebrate muscle and, 177–93
- Na,K-ATPase structure and mechanism, 817, 821–22, 835–36, 838–39
- paracrine factors in tubuloglomerular response and, 501, 508–14
- processive and nonprocessive models of kinesin movement, 161–72
- Adenovirus
- recombinant lung gene therapy and, 585, 588–90, 597
- Adenylyl cyclase
- gastric enterochromaffin-like cells and, 371–77
- Adipose tissue
- insulin receptor knockout mice and, 313–25
- liporegulation and, 333–44
- nuclear receptors in metabolism and, 261, 269–73
- A domain
- Na,K-ATPase structure and mechanism, 824, 832–38
- Adrenalectomy
- liporegulation and, 343
- mammalian urea transporters and, 551–52
- Adriamycin
- mammalian urea transporters and, 552
- AE1 protein
- hensin and terminal differentiation, 569–71, 576–77
- Afferent arterioles
- paracrine factors in tubuloglomerular response and, 502–4, 508–9
- Affinity modulation
- calcium channel permeation and selectivity, 134–36
- hensin and terminal differentiation, 579
- age1* mutant
- insulin receptor knockout mice and, 325
- Airway epithelium

- lung gene therapy and, 585-604
- akt* genes
- cardiac hypertrophy and, 49-51
  - insulin receptor knockout mice and, 325
- Albumin
- surfactant therapy for ALI/ARDS and, 618
- Aldosterone
- mammalian urea transporters and, 552
- ALEC surfactant
- surfactant therapy for ALI/ARDS and, 620, 625-26
- Altruism
- gastric biology of *Helicobacter pylori* and, 356
- Alveofact
- surfactant therapy for ALI/ARDS and, 620, 625-26
- Alveolar macrophages
- second messenger pathways in pulmonary host defense and, 642-57
- Alveolar type I epithelial cells
- animals, 674
  - aquaporin 5, 675-78
  - carboxypeptidase M, 681-82
  - caveolin-1, 678-81
  - cell injury, 685-87
  - cell types, 676-77
  - conclusions, 688
  - development, 684-85
  - early research, 671
  - enzymes, 683-84
  - experimental models, 687
  - fetus, 684-85
  - gene expression, 686-87
  - human homologs, 674-75
  - ICAM-1, 682-83
  - immunomodulation, 682-83
  - intact animals, 676-77
  - introduction, 669-70
  - in vitro type I cell models, 687
  - in vivo promoter specificity, 673-74
  - ion transporters, 683-84
  - lung, 680, 686-87
  - methylation, 673
  - non-lung precursor cells, 687-88
  - peptidolytic enzyme, 681-82
  - primary cells, 674
  - proteins, 683-84
  - receptors, 683-84
  - regulation, 672-74, 676-77, 679-80
  - signaling, 678-81
  - T1 $\alpha$ , 671-75
  - transcytosis, 678-81
  - water channel, 675-78
- Amiloride-sensitive channels
- transducing touch in *Caenorhabditis elegans* and, 429, 436-42
- Aminophospholipid
- asymmetry
  - aminophospholipid translocase, 704-5
  - apoptosis, 708-9, 711-18
  - blood clotting, 707-8
  - Caenorhabditis elegans* death (CED) proteins, 711, 713
  - calreticulin, 715
  - CD14, 714-15
  - CD93, 715
  - cell biogenesis, 706-7
  - complement receptors, 715
  - conclusions, 719-20
  - $\beta$ 2-glycoprotein I receptor, 715-16
  - homeostasis, 711
  - insect phagocyte receptors, 713-18
  - integrins, 714
  - introduction, 702
  - macrophage receptors, 711-13
  - mammalian receptors, 713-18
  - membrane lipid asymmetry, 706-11
  - Mer, 713
  - Mg<sup>2+</sup>-ATPase, 704-5
  - multidrug resistance proteins, 705-6
  - outer membrane leaflet, 703
  - phagocytosis of aberrant cells, 711-13
  - PS receptor, 718
  - PSOX, 717, 718
  - receptor redundancy, 718-19
  - red blood cell senescence and disease, 709-10
  - scavenger receptor superfamily
  - scavenger receptor class A (SRA), 716
  - scavenger receptor class B (SRB), 716-17
  - scavenger receptor class C (SRCL), 717
  - scavenger receptor class D (LAMP), 717
  - scavenger receptor class E (SREC), 717
  - scramblase, 706
  - trafficking of aminophospholipids to plasma membrane, 702, 704
  - transporter identification, 704-6
  - tumor cells and tumor vasculature, 710-11
  - wound repair, 707, 708
- Aminophospholipid

- translocase
- aminophospholipid
- asymmetry and, 704–5
- amiS* genes
- gastric biology of
- Helicobacter pylori* and, 349
- Amoxicillin
- gastric biology of
- Helicobacter pylori* and, 349, 364–65
- Amphiphysin
- gastric
- enterochromaffin-like cells and, 371, 376–77
- Amplification
- TRP channel regulation via
- lipid second messengers and, 745–47
- Anchoring
- phosphoinositides in
- membrane retrieval and insertion, 791–808
- Androgens
- history of research, 1–17
- Angiogenesis
- lipid receptors in
- cardiovascular development and, 23, 26–29
- Angiotensin II
- mammalian urea transporters and, 549, 552, 557
- paracrine factors in
- tubuloglomerular response and, 501, 506–7
- Anguilla rostrata*
- functional genomics and comparative physiology of hypoxia, 217
- Annexin
- aminophospholipid asymmetry and, 710
- Anser* spp.
- functional genomics and comparative physiology of hypoxia, 210
- $\alpha 1$ -Antitrypsin deficiency
- lung gene therapy and, 585, 587–89
- Apical K conductance
- macula densa cell signaling and, 485–86
- Apical membrane
- hensin and terminal differentiation, 567–80
- Apical pole remodeling
- acid secretion by parietal cell and, 103–23
- Apical positioning
- type IIa Na/Pi cotransporter and, 531–36
- Apolipoproteins
- nuclear receptors in
- metabolism and, 262, 274–77
- Apoptosis
- aminophospholipid asymmetry and, 701, 703, 708–9, 711–18
- liporegulation and, 333, 338, 340–44
- Appetite suppression
- insulin receptor knockout mice and, 323
- Aquaporins
- alveolar type I epithelial cells and, 675–78
- hensin and terminal differentiation, 575
- Arabidopsis thaliana*
- transducing touch in
- Caenorhabditis elegans* and, 441, 443
- Arachidonic acid
- TRP channel regulation via
- lipid second messengers and, 735–52
- Arf family GTPases
- phosphoinositide regulation of actin cytoskeleton and, 768
- L-Arginine
- mammalian urea transporters and, 554
- Arp2/3 complex
- phosphoinositide regulation of actin cytoskeleton and, 771–73
- Arterioles
- afferent
- paracrine factors in
- tubuloglomerular response and, 502–4, 508–9
- Artificial selection
- functional genomics and comparative physiology of hypoxia, 203–24
- ASC complexes
- transducing touch in
- Caenorhabditis elegans* and, 436–37
- asc* genes
- transducing touch in
- Caenorhabditis elegans* and, 441–42
- ASH ciliated sensory neurons
- transducing touch in
- Caenorhabditis elegans* and, 434–35
- Asthma
- surfactant therapy for
- ALI/ARDS and, 632
- Astrocytes
- NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20
- Asymmetry
- aminophospholipid, 701–20
- calcium channel permeation and selectivity, 141–44
- phosphoinositides in
- membrane retrieval and insertion, 791–97, 804–5
- Atherosclerosis
- nuclear receptors in
- metabolism and, 261, 268



- ATPases  
 V-type  
   gastric  
   enterochromaffin-like  
   cells and, 371-77
- ATP-binding cassette  
 transporter A1 (ABCA1)  
 nuclear receptors in  
 metabolism and, 262,  
 276-78
- Attenuation  
 cardiac hypertrophy and,  
 65
- Automaticity  
 hyperpolarization-activated  
 cation currents and,  
 466-69
- Autoregulation  
 paracrine factors in  
 tubuloglomerular  
 response and, 501,  
 509-10
- B**
- Bacteria  
 acid secretion by parietal  
 cell and, 107  
 gastric biology of  
*Helicobacter pylori* and,  
 349-65  
 gastric  
   enterochromaffin-like  
   cells and, 371, 377  
 lung gene therapy and, 587,  
 592  
 microarray technology and,  
 250  
 phosphoinositides in  
 membrane retrieval and  
 insertion, 806  
 second messenger  
 pathways in pulmonary  
 host defense and, 642-57  
 surfactant therapy for  
 ALI/ARDS and, 615
- Bacteriorhodopsin  
 G protein-coupled receptor  
   rhodopsin and, 866, 867
- BAPTA  
 hensin and terminal  
 differentiation, 578
- Basolateral channel  
 macula densa cell signaling  
 and, 481-95
- BATIRKO mice  
 insulin receptor knockout  
 mice and, 322
- Bauhinia purpurea*  
 alveolar type I epithelial  
 cells and, 683, 687
- BCECF  
 gastric biology of  
*Helicobacter pylori* and,  
 358
- bcl-2* gene  
 gastric  
   enterochromaffin-like  
   cells and, 377  
 liporegulation and, 341
- Biased diffusion model  
 processive and  
 nonprocessive models of  
 kinesin movement, 161,  
 170
- Bile acids  
 nuclear receptors in  
 metabolism and, 261,  
 280-86
- Bile salt export pump (BSEP)  
 nuclear receptors in  
 metabolism and, 262
- Biogenesis  
 membrane  
   mitochondrial variation  
   in vertebrate muscle  
   and, 184-85
- Birds  
 functional genomics and  
 comparative physiology  
 of hypoxia, 210-11
- BLES surfactant  
 surfactant therapy for  
 ALI/ARDS and, 619-20,  
 625-26
- Blood clotting  
 aminophospholipid  
 asymmetry and, 707-8
- Blood flow  
 macula densa cell signaling  
 and, 481-95
- Body wall  
 transducing touch in  
*Caenorhabditis elegans*  
 and, 429-46
- Brachydanio rerio*  
 transducing touch in  
*Caenorhabditis elegans*  
 and, 430
- Brain  
 hyperpolarization-activated  
 cation currents and,  
 461-62  
 insulin receptor knockout  
 mice and, 313-25  
 mammalian urea  
 transporters and, 558  
 NMR of glutamate  
 neurotransmitter flux and  
 neuroenergetics, 401-20
- Brown adipocytes  
 insulin receptor knockout  
 mice and, 322
- Brush border membrane  
 type IIa Na/Pi  
 cotransporter and, 531-36
- Bumps  
 quantum  
   TRP channel regulation  
   via lipid second  
   messengers and,  
   737-38, 746-47
- C**
- Ca-ATPase  
 Na,K-ATPase structure and  
 mechanism, 817-41
- Ca<sup>2+</sup>  
 gastric  
   enterochromaffin-like  
   cells and, 371, 373-74  
 macula densa cell signaling

- and, 481–95  
TRP channel regulation via  
lipid second messengers  
and, 735–52
- $\text{Ca}^{2+}$  channels  
permeation and selectivity  
in  
affinity, 134–36  
amino acid residues,  
137–41  
EEEE locus, 145  
functional asymmetry,  
141–44  
functional groups,  
144–46  
glutamates, 141–44  
high-affinity  $\text{Ca}^{2+}$   
binding region, 139–41  
introduction, 133–34  
 $\text{K}^{+}$  channels, 145–46  
multi-ion basis of  
selective permeability  
in Ca channels, 134–37  
multi-ion pore, 136–37  
non-selectivity filter  
domains, 146  
predicted structures,  
152–54  
probing side chain  
orientation, 145  
protonation, 145  
rate theory, 148–51  
selective ion transport,  
146–47  
selective permeability,  
134–47  
selectivity filter, 137–46  
structural  
approximations,  
151–52  
substituted-cysteine  
accessibility, 145  
summary, 154–55  
theories of Ca channel  
permeation, 147–54  
permeation and selectivity  
in, 133–55
- Caenorhabditis elegans*  
aminophospholipid  
asymmetry and, 711, 713  
functional genomics and  
comparative physiology  
of hypoxia, 205  
insulin receptor knockout  
mice and, 324–25  
microarray technology and,  
238, 242  
phosphoinositides in  
membrane retrieval and  
insertion, 806
- Calcineurin  
cardiac hypertrophy and,  
46–49
- Calcium channels  
TRP channel regulation via  
lipid second messengers  
and, 735–52
- Calliphora* spp.  
TRP channel regulation via  
lipid second messengers  
and, 748
- Caloric intake  
liporegulation and, 333–44
- Calpain  
acid secretion by parietal  
cell and, 121–22  
insulin receptor knockout  
mice and, 324
- Calpastatin  
acid secretion by parietal  
cell and, 122
- Calreticulin  
aminophospholipid  
asymmetry and, 712, 715
- Cancer  
aminophospholipid  
asymmetry and, 703,  
710–11  
gastric biology of  
*Helicobacter pylori* and,  
350–51, 365  
gastric  
enterochromaffin-like  
cells and, 371
- Capping  
phosphoinositide  
regulation of actin  
cytoskeleton and, 774–75
- CAR receptors  
lung gene therapy and, 588,  
602
- Carboxyl side chains  
calcium channel  
permeation and  
selectivity, 133–55
- Carboxypeptidase M  
alveolar type I epithelial  
cells and, 681–82
- Cardiac automaticity  
hyperpolarization-activated  
cation currents and,  
466–68
- Cardiac hypertrophy  
attenuation, 65  
calcineurin-NFAT  
signaling, 46–49  
CHAMP, 63, 64  
compensatory response,  
64–66  
gp130/STAT3 signaling,  
59–60  
G protein-coupled  
receptors, 53  
 $\text{G}_i$  signaling, 55  
 $\text{G}_s$  signaling, 54–55  
 $\text{Gq/G}_{11}$  signaling, 53–54  
inhibition, 64–66  
introduction, 45–46  
lipid metabolism, 60–62  
maladaptation, 64–66  
MAPK pathways, 57–58  
MEF2/HDAC, 52–53  
miscellaneous pathways,  
62–64  
MMP/TNF, 62–63  
molecular pathways, 46–62  
Na/H exchanger inhibition,  
63–64  
PI3K/Akt/  
GSK-3-dependent  
signaling, 49–51

- PKC, 58–59  
 sarcomeric signaling, 55–57  
 small GTP-binding proteins, 55–57  
 TNF, 62–63  
 transcriptional control, 52–53  
 Cardiomyopathy  
   liporegulation and, 337  
 Cardiovascular physiology  
   cardiac hypertrophy and, 45–66  
   lipid receptors in cardiovascular development and, 23–38  
   stress-activated cytokines and the heart, 81–95  
 Carnitine palmitoyl transferase  
   liporegulation and, 335–36  
 Catalytic cycle  
   Na,K-ATPase structure and mechanism, 832–38  
 $\beta$ -Catenin  
   second messenger pathways in pulmonary host defense and, 653  
 Cation channels  
   TRP channel regulation via lipid second messengers and, 749–51  
 Cationic liposome/DNA complexes  
   lung gene therapy and, 592–93, 597, 602  
 Cation specificity  
   Na,K-ATPase structure and mechanism, 831–32  
 Cation transport  
   Na,K-ATPase structure and mechanism, 817–41  
 Cattle  
   functional genomics and comparative physiology of hypoxia, 217  
 Caveolin-1  
   alveolar type I epithelial cells and, 678–81  
 Cavities  
   G protein-coupled receptor rhodopsin and, 868–69  
 CCO<sup>-3</sup>  
   hensin and terminal differentiation, 567–80  
 CD14 protein  
   aminophospholipid asymmetry and, 714–15  
 CD93 protein  
   aminophospholipid asymmetry and, 715  
 cDNA  
   hensin and terminal differentiation, 571  
   mammalian urea transporters and, 543–46, 548  
   microarray technology and, 238–40  
*cds* genes  
   TRP channel regulation via lipid second messengers and, 747  
 CED proteins  
   aminophospholipid asymmetry and, 711, 713  
 Cell biogenesis  
   aminophospholipid asymmetry and, 706–7  
 Cell membrane proteins  
   Na,K-ATPase structure and mechanism, 817–41  
 Cell migration  
   lipid receptors in cardiovascular development and, 27–28  
 Cell physiology  
   acid secretion by parietal cell and, 103–23  
   calcium channel permeation and selectivity, 133–55  
   processive and nonprocessive models of kinesin movement, 161–72  
 Cell proliferation  
   alveolar type I epithelial cells and, 669  
 Cell senescence  
   aminophospholipid asymmetry and, 709–10  
 Central nervous system (CNS)  
   hyperpolarization-activated cation currents and, 464–71  
 CEP ciliated sensory neurons transducing touch in *Caenorhabditis elegans* and, 435  
 Ceramide  
   liporegulation and, 333, 338–39, 342–43  
   second messenger pathways in pulmonary host defense and, 654–55  
 Cerebral cortex  
   NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
 Cerebral metabolic rate (CMR)  
   of oxygen consumption  
   NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
*c-fos* gene  
   functional genomics and comparative physiology of hypoxia, 221  
   gastric enterochromaffin-like cells and, 373  
 CFTR channel  
   lung gene therapy and, 587–89, 593–95, 598–602  
 CHAMP protein

- cardiac hypertrophy and, 63–64
- Chickens  
functional genomics and comparative physiology of hypoxia, 217–18
- Chimeric analysis  
gastric biology of *Helicobacter pylori* and, 349, 363
- Chinese hamster ovary (CHO) cells  
aminophospholipid asymmetry and, 703
- Chloephaga melanoptera*  
functional genomics and comparative physiology of hypoxia, 211
- Cholecystolinin (CCK)  
acid secretion by parietal cell and, 112
- Cholesterol  
history of research, 7–8  
nuclear receptors in metabolism and, 261–62, 273–84
- Cholesterol ester transfer protein (CETP)  
nuclear receptors in metabolism and, 262, 275, 278–79
- Cholesterol 7  $\alpha$ -hydroxylase (CYP7A1)  
nuclear receptors in metabolism and, 262, 267, 279–83, 286
- Cholinergic pathways  
acid secretion by parietal cell and, 109–11
- Chromogranin A promoter  
gastric acid secretion in genetically engineered mice and, 394  
gastric enterochromaffin-like cells and, 371, 373, 375
- Chromophore-binding sites  
G protein-coupled receptor rhodopsin and, 851, 863–65, 868–69
- Chronic acid resistance  
gastric biology of *Helicobacter pylori* and, 363–64
- cis*-activation  
lung gene therapy and, 599
- 11-*cis*-retinal  
G protein-coupled receptor rhodopsin and, 851–71
- c-jun* gene  
functional genomics and comparative physiology of hypoxia, 221  
gastric enterochromaffin-like cells and, 373
- $\text{Cl}^-$   
gastric enterochromaffin-like cells and, 371, 373–74  
macula densa cell signaling and, 481–95
- $\text{Cl}^-:\text{HCO}_3^-$  exchange  
hensin and terminal differentiation, 569–70
- Clarithromycin  
gastric biology of *Helicobacter pylori* and, 349, 364–65
- Clathrin coat proteins  
acid secretion by parietal cell and, 115
- Cloning  
microarray technology and, 238–40
- Clustering  
phosphoinositide regulation of actin cytoskeleton and, 761
- Coactivators  
nuclear receptors in metabolism and, 263
- Coat proteins  
phosphoinositides in membrane retrieval and insertion, 791–808
- Cofactors  
Na,K-ATPase structure and mechanism, 817–41  
paracrine factors in tubuloglomerular response and, 501–20
- Cofilin/ADF  
phosphoinositide regulation of actin cytoskeleton and, 773–74
- Collagen  
hensin and terminal differentiation, 571, 573
- Colon cancer  
aminophospholipid asymmetry and, 710
- Combinatorial synthesis  
of genetic networks  
functional genomics and comparative physiology of hypoxia, 213
- Comparative physiology  
functional genomics and comparative physiology of hypoxia, 203–24  
microarray technology and, 231–51  
mitochondrial variation in vertebrate muscle and, 177–93
- Compensatory response  
cardiac hypertrophy and, 64–66
- Complement receptors  
aminophospholipid asymmetry and, 715
- Conditional ablation  
insulin receptor knockout mice and, 318
- Cone visual pigments  
G protein-coupled receptor rhodopsin and, 869

- Congenital generalized  
   lipodystrophy  
   liporegulation and, 335–38  
*connexin 43* gene  
   second messenger  
     pathways in pulmonary  
     host defense and, 653  
 Consomic panels  
   functional genomics and  
   comparative physiology  
   of hypoxia, 203, 209–10  
 Contractile activity  
   cardiac hypertrophy and,  
   45–66  
   mitochondrial variation in  
   vertebrate muscle and,  
   177–93  
 Coregulators  
   nuclear receptors in  
   metabolism and, 261  
 Corepressors  
   nuclear receptors in  
   metabolism and, 263  
 Cortical collecting tubule  
   hensin and terminal  
   differentiation, 567–80  
 Corticosterone  
   hensin and terminal  
   differentiation, 569  
 Cortisol  
   liporegulation and, 343–44  
 Cotransporters  
   macula densa cell signaling  
   and, 483–91  
   type IIa Na/Pi  
   cotransporter and, 531–36  
 CpG dinucleotides  
   lung gene therapy and, 592  
 Cre/loxP system  
   insulin receptor knockout  
   mice and, 316–20,  
   322–23  
 Crosstalk  
   aminophospholipid  
   asymmetry and, 701–20  
   phosphoinositide  
   regulation of actin  
   cytoskeleton and, 775,  
   761  
*crq* gene  
   aminophospholipid  
   asymmetry and, 713  
 Cryo-electron microscopy  
   G protein-coupled receptor  
   rhodopsin and, 866–67  
 Crystal structure  
   G protein-coupled receptor  
   rhodopsin and, 851,  
   857–67  
*cup-5* gene  
   transducing touch in  
   *Caenorhabditis elegans*  
   and, 444  
*Cupiennius salei*  
   transducing touch in  
   *Caenorhabditis elegans*  
   and, 433, 437  
 Curosurf  
   surfactant therapy for  
   ALI/ARDS and, 620  
 Cushing's syndrome  
   liporegulation and, 333,  
   343  
 Cyclic adenosine  
   monophosphate (cAMP)  
   acid secretion by parietal  
   cell and, 103–23  
   paracrine factors in  
   tubuloglomerular  
   response and, 501–20  
*cyclin D1* gene  
   second messenger  
   pathways in pulmonary  
   host defense and, 653  
 Cysteine  
   calcium channel  
   permeation and  
   selectivity, 145  
 Cystic fibrosis  
   lung gene therapy and,  
   585–87, 593–96, 598–603  
   surfactant therapy for  
   ALI/ARDS and, 632  
 Cytochrome 3A (CYP3A)  
   nuclear receptors in  
   metabolism and, 262,  
   266–67, 284–87  
 Cytokines  
   liporegulation and, 343  
   second messenger  
   pathways in pulmonary  
   host defense and, 642–57  
   stress-activated cytokines  
   and the heart, 81–95  
 Cytoplasmic domains  
   Na,K-ATPase structure and  
   mechanism, 817, 832–37  
 Cytoskeleton  
   acid secretion by parietal  
   cell and, 103–23  
   actin-based  
     acid secretion by parietal  
     cell and, 118–22  
   phosphoinositide  
   regulation and, 761–80  
 Cytosol  
   macula densa cell signaling  
   and, 481, 489–90  
 Cytotoxic T-lymphocytes  
   lung gene therapy and, 591

## D

- daf* mutants  
   insulin receptor knockout  
   mice and, 324–25  
*dauer* stage  
   insulin receptor knockout  
   mice and, 324–25  
 dDAVP  
   mammalian urea  
   transporters and, 548,  
   550, 555  
 Defensins  
   lung gene therapy and, 597  
 DEG/EnaC channels  
   transducing touch in  
   *Caenorhabditis elegans*  
   and, 429, 436–42  
*del-1* gene  
   transducing touch in  
   *Caenorhabditis elegans*

- and, 438–39, 441–42
- Deletion mutants
- gastric biology of
  - Helicobacter pylori* and, 349, 360–62
  - phosphoinositide regulation of actin cytoskeleton and, 769–70
- Dendritic actin nucleation
- phosphoinositide regulation of actin cytoskeleton and, 771
- Dendritic integration
- hyperpolarization-activated cation currents and, 453, 465–66
- Dephosphorylation
- Na,K-ATPase structure and mechanism, 840
- Detoxification
- nuclear receptors in metabolism and, 284–87
- Deuterostomes
- stress-activated cytokines and the heart, 84–85
- Development
- alveolar type I epithelial cells and, 669–88
  - insulin receptor knockout mice and, 313, 316–17, 323
  - lipid receptors in cardiovascular development and, 23, 29–37
  - mammalian urea transporters and, 551, 554
  - mitochondrial variation in vertebrate muscle and, 177, 187–89
- Dexamethasone
- mammalian urea transporters and, 547, 551–52
- Diabetes
- aminophospholipid asymmetry and, 703, 709
  - insulin receptor knockout mice and, 313, 317–19, 321–25
  - liporegulation and, 337–39, 343
  - mammalian urea transporters and, 552
  - nuclear receptors in metabolism and, 261, 268, 272–73
  - paracrine factors in tubuloglomerular response and, 501, 518–20
- Diacylglycerol
- liporegulation and, 342
  - TRP channel regulation via lipid second messengers and, 749–50
- Diacylglycerol kinase
- TRP channel regulation via lipid second messengers and, 735–52
- Dictyostelium discoideum*
- phosphoinositides in membrane retrieval and insertion, 799
- Dietary fat
- lipid receptors in cardiovascular development and, 23–38
  - liporegulation and, 333–44
- Differentiation
- mitochondrial variation in vertebrate muscle and, 177, 187–89
  - nuclear receptors in metabolism and, 269–70
- Dihydrotachysterol
- mammalian urea transporters and, 555
- Dihydrotestosterone
- history of research, 1, 9–10, 14–16
- Dilated cardiomyopathy
- liporegulation and, 340
- Dimerization
- G protein-coupled receptor rhodopsin and, 857–58
  - nuclear receptors in metabolism and, 262–63
- Dimethyl maleic anhydride (DMMA)
- hensin and terminal differentiation, 572
- Dipeptidyl peptidase IV
- hensin and terminal differentiation, 576
- Directionality
- processive and nonprocessive models of kinesin movement, 163
- DiSC3
- gastric biology of
  - Helicobacter pylori* and, 358
- Discovery science
- functional genomics and comparative physiology of hypoxia, 223
- Disease
- aminophospholipid asymmetry and, 703, 709–10, 713
  - gastric biology of
  - Helicobacter pylori* and, 349–65
  - G protein-coupled receptor rhodopsin and, 863
  - hyperpolarization-activated cation currents and, 471
  - liporegulation and, 333–44
  - nuclear receptors in metabolism and, 261, 268–87
- Diving mammals
- functional genomics and comparative physiology of hypoxia, 214
- DMBT1* gene
- hensin and terminal differentiation, 571
- DNA laddering

- liporegulation and, 340-41
- Domestic animal studies
- functional genomics and comparative physiology of hypoxia, 217-19
- Drosophila* spp.
- aminophospholipid asymmetry and, 713
- G protein-coupled receptor
- rhodopsin and, 852
- microarray technology and, 232, 241-42
- mitochondrial variation in vertebrate muscle and, 187
- nuclear receptors in
- metabolism and, 266-67
  - processive and nonprocessive models of kinesin movement, 165
  - second messenger pathways in pulmonary host defense and, 644
- transducing touch in *Caenorhabditis elegans* and, 430, 432, 437, 441-44
- TRP channel regulation via lipid second messengers and, 735-52
- type IIa Na/Pi cotransporter and, 531-36
- DRS2* gene
- aminophospholipid asymmetry and, 705
- Drug-drug interactions
- nuclear receptors in metabolism and, 286-87
- DsMit* gene
- functional genomics and comparative physiology of hypoxia, 208
- Dual vector approaches
- lung gene therapy and, 598-99
- Duodenal peptides
- acid secretion by parietal cell and, 112
- Dynamin
- acid secretion by parietal cell and, 116
  - gastric enterochromaffin-like cells and, 371, 376-77
- E**
- E<sub>1</sub>-E<sub>2</sub> transitions
- Na,K-ATPase structure and mechanism, 817, 835
- EBP50
- acid secretion by parietal cell and, 121
- Ecology
- functional genomics and comparative physiology of hypoxia, 215-16
- Ecto-5'-nucleotidase\*
- paracrine factors in tubuloglomerular response and, 501, 513
- Ectopic lipid deposition
- liporegulation and, 333
- Edema
- surfactant therapy for ALI/ARDS and, 615, 624
- EDG receptors
- lipid receptors in cardiovascular development and, 28-37
- EEEE locus
- calcium channel permeation and selectivity, 133-55
- Effectors
- acid secretion by parietal cell and, 103-23
  - phosphoinositides in membrane retrieval and insertion, 791-808
- Electrolytes
- hensin and terminal differentiation, 567-80
  - macula densa cell signaling and, 481-95
- mammalian urea transporters and, 543
  - paracrine factors in tubuloglomerular response and, 501-20
  - type IIa Na/Pi cotransporter and, 531-36
- Electrophysiology
- TRP channel regulation via lipid second messengers and, 737-38
- Electrostatic interactions
- phosphoinositide regulation of actin cytoskeleton and, 764
- Embryonic growth
- insulin receptor knockout mice and, 313
- ENaC epithelial ion channel
- lung gene therapy and, 593
- Endobiotics
- nuclear receptors in metabolism and, 261-87
- Endocrinology
- acid secretion by parietal cell and, 103-23
  - insulin receptor knockout mice and, 313-25
  - nuclear receptors in metabolism and, 261-87
- Endocytosis
- gastric enterochromaffin-like cells and, 371, 376-77
  - hensin and terminal differentiation, 567-80
  - phosphoinositides in membrane retrieval and insertion, 791-808
  - type IIa Na/Pi cotransporter and, 531-36
- Endosomes
- lung gene therapy and, 593
  - phosphoinositides in membrane retrieval and insertion, 791-808
- Endothelins



- hensin and terminal differentiation, 578
- Energy homeostasis  
nuclear receptors in metabolism and, 271–72
- Energy metabolism  
insulin receptor knockout mice and, 313–25  
mitochondrial variation in vertebrate muscle and, 178–83, 190–92  
nuclear receptors in metabolism and, 261
- Energy transduction  
Na,K-ATPase structure and mechanism, 832–40
- Enterochromaffin-like (ECL) cells  
Ca<sup>2+</sup> channels, 373–74  
Cl<sup>−</sup> channels, 373–74  
endocytosis, 376–77  
exocytosis, 375–76  
gastric acid secretion in genetically engineered mice and, 383–96  
histamine storage, 374–75  
K<sup>+</sup> channels, 373–74  
pathophysiology in chronic gastritis, 377  
physiological stimulants and inhibitors of function, 371–73
- Enterohepatic circulation  
nuclear receptors in metabolism and, 282–84
- Entorhinal cortex neurons  
hyperpolarization-activated cation currents and, 469
- Env* gene  
lung gene therapy and, 589, 592
- Environmental factors  
functional genomics and comparative physiology of hypoxia, 222–23  
nuclear receptors in metabolism and, 261
- transducing touch in *Caenorhabditis elegans* and, 433–34
- Environmental physiology  
microarray technology and, 231–51
- Epidermal growth factor (EGF)  
acid secretion by parietal cell and, 111–12
- Epithelial cells  
alveolar type I epithelial cells and, 669–88  
gastric acid secretion in genetically engineered mice and, 383–96  
hensin and terminal differentiation, 567–80
- Equines  
functional genomics and comparative physiology of hypoxia, 218–19
- Erythrocytes  
aminophospholipid asymmetry and, 703, 706  
mammalian urea transporters and, 543–58
- Escherichia coli*  
functional genomics and comparative physiology of hypoxia, 211, 213  
gastric biology of *Helicobacter pylori* and, 350, 354  
microarray technology and, 244  
transducing touch in *Caenorhabditis elegans* and, 431, 446
- Estrogen excess  
history of research, 12–13
- ETB receptor  
hensin and terminal differentiation, 578
- Eukaryotic cells  
phosphoinositides in membrane retrieval and insertion, 791–808
- Evolution  
functional genomics and comparative physiology of hypoxia, 203–24  
microarray technology and, 231–51  
mitochondrial variation in vertebrate muscle and, 177–93
- Excitation  
TRP channel regulation via lipid second messengers and, 738–45
- Exercise  
insulin receptor knockout mice and, 323  
mitochondrial variation in vertebrate muscle and, 177–93
- Exocytosis  
gastric enterochromaffin-like cells and, 371, 375–76  
phosphoinositides in membrane retrieval and insertion, 800–3, 806–7  
surfactant therapy for ALI/ARDS and, 616
- Exosurf  
surfactant therapy for ALI/ARDS and, 620, 625–26
- Experimental evolution  
functional genomics and comparative physiology of hypoxia, 213
- Expression analysis  
microarray technology and, 238–41
- Extra-renal urea transporters  
mammalian urea transporters and, 558
- Extracellular matrix  
hensin and terminal differentiation, 567–80
- Ezrin



- acid secretion by parietal cell and, 120–22
- Ezrin/radixin/moesin (ERM) proteins
- phosphoinositide regulation of actin
- cytoskeleton and, 777
- F**
- Farnesyl X receptor (FXR)
- nuclear receptors in metabolism and, 261–62, 266, 278–79
- FAS protein
- liporegulation and, 336
- Fat tolerance
- liporegulation and, 333–44
- Fatty acid-binding protein (FABP)
- nuclear receptors in metabolism and, 269
- Fatty acids
- insulin receptor knockout mice and, 320
- liporegulation and, 337–38, 340, 342
- nuclear receptors in metabolism and, 261, 271
- Fatty acid synthase
- liporegulation and, 335
- Fertility impairment
- insulin receptor knockout mice and, 319–20, 323
- Fetal development
- alveolar type I epithelial cells and, 684–85
- Fibrinogen
- hensin and terminal differentiation, 579
- surfactant therapy for ALI/ARDS and, 618
- Fibronectin
- hensin and terminal differentiation, 571, 579
- Filamin
- phosphoinositide regulation of actin
- cytoskeleton and, 776–77
- FIRKO mice
- insulin receptor knockout mice and, 320–21
- Fish
- functional genomics and comparative physiology of hypoxia, 210, 214
- Flopases
- aminophospholipid asymmetry and, 705
- FLP ciliated sensory neurons transducing touch in *Caenorhabditis elegans* and, 434–35
- Flux
- calcium channel permeation and selectivity, 133–55
- NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20
- Force sensitivity
- transducing touch in *Caenorhabditis elegans* and, 429, 433–36
- Forestomach
- gastric acid secretion in genetically engineered mice and, 395
- Foxo* mutations
- insulin receptor knockout mice and, 325
- fra-1* gene
- second messenger pathways in pulmonary host defense and, 653
- Free fatty acids
- liporegulation and, 338
- nuclear receptors in metabolism and, 271
- Fuel homeostasis
- insulin receptor knockout mice and, 313–25
- Fugu rubripes*
- transducing touch in *Caenorhabditis elegans* and, 441, 443–44
- Functional activation
- NMR of glutamate neurotransmitter flux and neuroenergetics, 410–11
- Functional asymmetry
- calcium channel permeation and selectivity, 141–44
- Functional genomics
- comparative physiology of hypoxia and, 203–24
- Functional magnetic resonance imaging (fMRI)
- NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20
- Fundulus heteroclitus*
- microarray technology and, 239
- Furosemide
- mammalian urea transporters and, 551, 556
- FYVE domain
- phosphoinositides in membrane retrieval and insertion, 791–95, 797, 807
- G**
- Gag* gene
- lung gene therapy and, 589, 592
- $\beta$ -Galactosidase
- liporegulation and, 341
- Galectin
- hensin and terminal differentiation, 572–73, 578
- Gallbladder disease
- nuclear receptors in metabolism and, 261, 268
- Gallus domesticus*
- functional genomics and comparative physiology of hypoxia, 217–18

- Gas exchange  
  alveolar type I epithelial cells and, 669
- Gastric acid  
  acid secretion by parietal cell and, 103–23  
  acid secretion in genetically engineered mice and, 383–96
- Gastric carcinoma  
  aminophospholipid asymmetry and, 710  
  gastric biology of *Helicobacter pylori* and, 349, 351, 365  
  gastric enterochromaffin-like cells and, 371
- Gastric mucosal pathway  
  gastric acid secretion in genetically engineered mice and, 390–91
- Gastrin  
  acid secretion by parietal cell and, 103–23  
  gastric acid secretion in genetically engineered mice and, 383–96  
  gastric biology of *Helicobacter pylori* and, 351  
  gastric enterochromaffin-like cells and, 371–77
- Gastritis  
  chronic  
    gastric enterochromaffin-like cells and, 377
- Gastrointestinal physiology  
  gastric acid secretion in genetically engineered mice and, 383–86  
  gastric biology of *Helicobacter pylori* and, 349–65  
  gastric enterochromaffin-like cells and, 371–77  
  nuclear receptors in metabolism and, 280–84  
  surfactant therapy for ALI/ARDS and, 613–14
- G cells  
  gastric acid secretion in genetically engineered mice and, 394–95
- Gelsolin  
  lung gene therapy and, 596  
  phosphoinositide regulation of actin cytoskeleton and, 774–75
- Gene therapy  
  for inherited lung diseases  
    airway gene therapy targets for cystic fibrosis, 593–96  
    airway stem cell targets for gene therapy, 595–96  
   $\alpha 1$ -antitrypsin deficiency, 587  
  barriers to gene transfer in lung, 596–98  
  cationic liposome/DNA complexes, 592–93, 602  
  CFTR, 594, 595  
  clinical trials, 601–3  
  cystic fibrosis, 586–603  
  dual vector approaches capable of expanding rAAV packaging capacity, 598–99  
  future research, 603–4  
  immunologic barriers to gene delivery in lung, 596–97  
  intracellular barriers to viral transduction, 597–98  
  introduction, 585–86  
  new technologies, 598–601  
  phenotype, 594, 595  
  physical barriers to gene delivery in lung, 596–97  
  polarity of airway epithelial gene transfer, 597–98  
  recombinant adeno-associated virus, 590–603  
  recombinant adenovirus, 588–90  
  recombinant lentiviruses, 592  
  recombinant retroviruses, 592  
  self-complementing rAAV vectors, 599–600  
  spliceosome-mediated *trans*-splicing, 600  
  targets, 586–87  
  vectors, 588–93
- Genetic ablation studies  
  insulin receptor knockout mice and, 313–25
- Genetic deletion  
  hyperpolarization-activated cation currents and, 471–72
- Genetic engineering  
  gastric acid secretion in genetically engineered mice and, 383–96
- Genetic networks  
  combinatorial synthesis of functional genomics and comparative physiology of hypoxia, 213
- Genetic screens  
  transducing touch in *Caenorhabditis elegans* and, 429–46
- Gene transcripts  
  microarray technology and, 231–51

- Genomics  
 functional genomics and comparative physiology of hypoxia, 203–24  
 microarray technology and, 231–51
- Gillichthys mirabilis*  
 functional genomics and comparative physiology of hypoxia, 210  
 microarray technology and, 242, 246, 248
- GL-67 cationic lipid  
 formulation  
 lung gene therapy and, 593
- Glial cells  
 NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20
- Glomerular filtration  
 macula densa cell signaling and, 481–95
- Glucagon  
 liporegulation and, 335
- Glucocorticoids  
 liporegulation and, 343  
 mammalian urea transporters and, 543, 547, 551–52
- Glucocorticoids  
 mammalian urea transporters and, 552
- Glucokinase  
 insulin receptor knockout mice and, 317, 322  
 liporegulation and, 340–41
- Glucose  
 insulin receptor knockout mice and, 313  
 liporegulation and, 335, 337, 341  
 NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
 nuclear receptors in metabolism and, 261, 269–73
- GLUT2 glucose transporter  
 insulin receptor knockout mice and, 317  
 liporegulation and, 340–41  
 nuclear receptors in metabolism and, 272
- GLUT4 glucose transporter  
 insulin receptor knockout mice and, 319–21  
 nuclear receptors in metabolism and, 272
- Glutamate  
 calcium channel permeation and selectivity, 133–55
- Glutamate-glutamine cycle  
 NMR of neurotransmitter flux and neuroenergetics cerebral cortex, 406–8  
 cerebral metabolic rate, 413–16  
 conclusions, 419–20  
 fMRI, 414–18  
 functional activation, 410–11  
 glial activity, 403–6  
 glucose oxidation, 408–12  
 glycogen shunt, 413  
 introduction, 402–3  
 in vivo  $^{13}\text{C}$  MRS, 403–11  
 lactate efflux, 413  
 lactate generation, 411–12  
 neuronal activity, 403–17  
 non-oxidative glycolysis, 411  
 oxidative glycolysis, 411  
 resting neuronal activity, 418  
 summary, 419–20  
 total neuroenergetics, 416–17
- Glycerol  
 insulin receptor knockout mice and, 320
- Glycogen shunt  
 NMR of glutamate neurotransmitter flux and neuroenergetics, 413
- Glycolysis  
 NMR of glutamate neurotransmitter flux and neuroenergetics, 411
- $\beta 2$ -Glycoprotein I ( $\beta 2\text{GPI}$ ) receptor  
 aminophospholipid asymmetry and, 715–16
- Gobiidae*  
 functional genomics and comparative physiology of hypoxia, 214
- gp130 receptor  
 cardiac hypertrophy and, 59–60
- GPAT protein  
 liporegulation and, 336
- GPI-linked proteins  
 hensin and terminal differentiation, 576
- G protein-coupled receptor  
 rhodopsin (GPCR)  
 activation mechanism  
 cavities, 868–69  
 chromophore-binding site, 868–69  
 unified model, 867–68  
 conclusions, 870–71  
 cone visual pigments, 869  
 crystal structure  
 bacteriorhodopsin, 866–67  
 chromophore-binding site, 863–65  
 cryo-electron microscopy, 866–67  
 crystallization, 857  
 crystallographic lattice, 857–58  
 data analysis, 857  
 dimers, 857–58

- functional regions, 865–66
- helices, 860–63
- human diseases
  - associated with mutation in rhodopsin gene, 863
- interhelical reactions, 860–63
- previous models, 866
- structural constraints, 865–66
- three-dimensional model, 858–59
- two-dimensional model, 859–60
- historical perspective, 851–53
- introduction, 851–53
- other G protein-coupled receptors, 869–70
- rhodopsin
  - composition, 854–55
  - expression, 853
  - mutagenesis, 856
  - photobleaching pathway, 855–56
  - purification, 853–54
  - regeneration, 855–56
- G proteins
  - cardiac hypertrophy and, 55–57
  - lipid receptors in cardiovascular development and, 23–38
  - paracrine factors in tubuloglomerular response and, 501–20
  - phosphoinositide regulation of actin cytoskeleton and, 767–68
- Gram-negative bacteria
  - gastric biology of *Helicobacter pylori* and, 349
  - gastric enterochromaffin-like cells and, 371, 377
- Growth retardation
  - insulin receptor knockout mice and, 313, 316–17, 323
- GSK-3 $\beta$  kinase
  - cardiac hypertrophy and, 49–51
- GW-501516
  - nuclear receptors in metabolism and, 264
- H**
- H<sup>+</sup>
  - gastric biology of *Helicobacter pylori* and, 354
  - hensin and terminal differentiation, 567–80
- H,K-ATPase
  - acid secretion by parietal cell and, 112–18
  - Na,K-ATPase structure and mechanism, 817–41
- H(Na)-K ATPase
  - macula densa cell signaling and, 481–95
- Hand-over-hand model
  - processive and nonprocessive models of kinesin movement, 161, 168–70
- Hantavirus
  - functional genomics and comparative physiology of hypoxia, 216
- Haploinsufficiency
  - insulin receptor knockout mice and, 313, 323–25
- HCl secretion
  - acid secretion by parietal cell and, 103–23
- HCN channels
  - hyperpolarization-activated cation currents and, 453–72
- HDAC proteins
  - cardiac hypertrophy and, 52–53
- Heart
  - cardiac hypertrophy and, 45–66
  - hyperpolarization-activated cation currents and, 453, 462–71
  - liporegulation and, 335, 337–38, 340
  - mammalian urea transporters and, 543, 557–58
  - stress-activated cytokines and, 81–95
- Heat map
  - microarray technology and, 237
- Helices
  - G protein-coupled receptor rhodopsin and, 860–63
  - Na,K-ATPase structure and mechanism, 817–41
- Helicobacter pylori*
  - gastric biology of acid resistance mechanisms, 353–64
  - acute acid resistance, 354–63
  - chronic acid resistance, 363–64
  - eradication, 364–65
  - habitat, 351–52
  - intrabacterial disease, 354–59
  - introduction, 350–51
  - nature of organism, 352–53
  - proton motive force, 354–59
  - time-independent acid resistance, 354
  - urease, 364
  - urea transport, 359–62
  - UreI, 362–63
  - gastric enterochromaffin-like

- cells and, 371, 377
- Helisoma trivolvis*  
transducing touch in  
*Caenorhabditis elegans*  
and, 441
- Helix aspersa*  
transducing touch in  
*Caenorhabditis elegans*  
and, 441
- Helix packing stability  
Na,K-ATPase structure and  
mechanism, 825-28
- Hemodynamics  
renal  
macula densa cell  
signaling and, 481-95
- Hemoglobin  
surfactant therapy for  
ALI/ARDS and, 618
- Hensin  
terminal differentiation of  
intercalated cells and,  
567-80
- Heparan sulfate proteoglycan  
lung gene therapy and, 591
- Hepatic nuclear factor 4 $\alpha$   
(HNF4- $\alpha$ )  
nuclear receptors in  
metabolism and, 262
- Heteromeric protein  
complexes  
type IIa Na/Pi  
cotransporter and, 531-36
- High-affinity Ca<sup>2+</sup> binding  
region  
calcium channel  
permeation and  
selectivity, 139-41
- High-density lipoprotein  
(HDL)  
nuclear receptors in  
metabolism and, 262,  
273-80
- High-density seeding  
in vivo  
hensin and terminal  
differentiation, 578-79
- High-frequency oscillation  
(HFO)  
surfactant therapy for  
ALI/ARDS and, 631
- Histamine  
acid secretion by parietal  
cell and, 103-23  
gastric acid secretion in  
genetically engineered  
mice and, 383-96  
gastric  
enterochromaffin-like  
cells and, 371-77
- Histidine decarboxylase  
(HDC)  
gastric  
enterochromaffin-like  
cells and, 371-75
- HL-10 surfactant  
surfactant therapy for  
ALI/ARDS and, 620
- HNP proteins  
lung gene therapy and, 597
- Homeostasis  
aminophospholipid  
asymmetry and, 701, 711  
gastric acid secretion in  
genetically engineered  
mice and, 383-96  
insulin receptor knockout  
mice and, 313-25  
liporegulation and, 333-44  
nuclear receptors in  
metabolism and, 270-73  
phosphoinositide  
regulation of actin  
cytoskeleton and, 764-65
- Homology models  
Na,K-ATPase structure and  
mechanism, 817-41
- Hormones  
gastric  
enterochromaffin-like  
cells and, 371  
history of research, 1-17
- Host defense  
pulmonary  
second messenger  
pathways in, 642  
"Hula Twist" mechanism  
G protein-coupled receptor  
rhodopsin and, 855
- 11 $\beta$ -Hydroxysteroid-  
dehydrogenase-1  
(11 $\beta$ -HSD-1)  
liporegulation and, 343
- Hyperfiltration  
paracrine factors in  
tubuloglomerular  
response and, 501, 519
- Hypergastrinemia  
gastric acid secretion in  
genetically engineered  
mice and, 383-96
- Hyperlipidemia  
nuclear receptors in  
metabolism and, 261,  
268
- Hyperphagia  
liporegulation and, 338
- Hyperpolarization-activated  
cation currents (I<sub>h</sub>)  
basic properties, 454-56  
brain, 461-62  
cardiac automaticity,  
466-68  
central nervous system,  
464-71  
cerebellar Purkinje cells,  
469  
conclusions, 472  
dendritic integration,  
465-66  
disease, 471  
entorhinal cortex neurons,  
469  
general principles, 456-59  
genetic deletion  
experiments, 471-72
- HCN channel function,  
459-61
- heart, 462-71
- historical perspective,  
454-56

- introduction, 453–54
  - neuronal automaticity, 468–69
  - physiological role, 456–71
  - primary pacemaking, 468–69
  - resting potential, 464–65
  - safety net for automaticity, 469
  - sensory signal
    - transduction, 464–65
  - spontaneous firing, 469
  - subthreshold oscillations, 469
  - subunit assembly, 463–64
  - synaptic transmission, 470–71
  - thalamocortical relay neurons, 468–69
  - Hypertrophic signaling
    - cardiac hypertrophy and, 45–66
  - Hypochlorhydria
    - gastric enterochromaffin-like cells and, 371
  - Hypoglycemia
    - insulin receptor knockout mice and, 315, 317–18
  - Hypoxia
    - functional genomics and comparative physiology of
      - air-breathing fishes, 214
      - birds, 210–11
      - cattle, 217
      - chickens, 217–18
      - combinatorial synthesis of genetic networks, 213
      - comparative molecular physiology, 216–17
      - conclusions, 223–24
      - consomic panels, 209–10
      - discovery science vs hypothesis testing, 223
      - diving mammals, 214
      - domestic animal studies, 217–19
      - environmental forces in natural selection, 222–23
      - equines, 218–19
      - evolutionary mechanisms, 220–21
      - experimental evolution, 213
      - fish, 210, 214
      - future studies, 220–23
      - gene expression, 205–6, 221
      - human studies, 219
      - inbred strains of mice, 207–8
      - introduction, 203–5
      - linkage analysis, 208
      - model organisms, 205–10
      - phylogenetically-independent contrasts, 214
      - phylogenetics, 220
      - physiological ecology, 215–16
      - physiological profiling, 211–12
      - rats, 208–10
      - segregation analysis, 207–8
      - selective breeding, 207–9, 212–13
      - systems biology, 213
      - transgenic mice, 206–7
      - types of hypoxia, 221–22
- I**
- Igf* receptors
    - insulin receptor knockout mice and, 313–25
  - IL1 neurons
    - transducing touch in *Caenorhabditis elegans* and, 435
  - Ileal bile acid-binding protein (I-BABP)
    - nuclear receptors in metabolism and, 262
  - Ileal bile acid transporter (I-BAT)
    - nuclear receptors in metabolism and, 262, 266
  - Immune response
    - alveolar type I epithelial cells and, 682–83
    - aminophospholipid asymmetry and, 701–20
    - lung gene therapy and, 596–97
    - surfactant therapy for ALI/ARDS and, 615
  - InaD* gene
    - TRP channel regulation via lipid second messengers and, 746
  - Inchworm model
    - processive and nonprocessive models of kinesin movement, 161, 168–70
  - Inducible nitric oxide synthase (iNOS)
    - liporegulation and, 341–42
  - Infasurf
    - surfactant therapy for ALI/ARDS and, 619–20, 625
  - Infection
    - second messenger pathways in pulmonary host defense and, 642–57
  - Inflammatory response
    - alveolar type I epithelial cells and, 642–57
    - second messenger pathways in pulmonary host defense and, 642
  - Inner medullary collecting duct

- mammalian urea transporters and, 543, 545-46, 548-51, 555-56
- Inner membrane leaflet aminophospholipid asymmetry and, 701-20
- Inositol TRP channel regulation via lipid second messengers and, 735-52
- Inositol triphosphate (PIP<sub>3</sub>) insulin receptor knockout mice and, 320, 322, 324-25
- Input conductance hyperpolarization-activated cation currents and, 453-72
- Insect phagocyte receptors aminophospholipid asymmetry and, 713-18
- Inside-out signaling hensin and terminal differentiation, 579
- InsP<sub>3</sub> TRP channel regulation via lipid second messengers and, 739-41
- INSR* gene insulin receptor knockout mice and, 315-18
- Insulin receptor knockout mice adipose tissue, 320-22 brown adipocytes, 322 conclusions, 325 conditional ablation, 318 diabetes, 323-25 differences between humans and mice lacking *INSR*, 315-18 generalized ablation of insulin receptors, 314-23 growth effects, 316 haploinsufficiency, 323-25 introduction, 313-14 metabolic effects, 317-18 nestin-positive neurons, 322-23 pancreatic  $\beta$ -cells, 321-22 skeletal muscle, 318-20
- Insulin resistance insulin receptor knockout mice and, 321, 324 liporegulation and, 337 nuclear receptors in metabolism and, 261, 268, 271-72
- Integrins aminophospholipid asymmetry and, 712, 714
- Intercalated cells terminal differentiation and, 567-80
- Intercellular adhesion molecule-1 (ICAM-1) alveolar type I epithelial cells and, 682-83
- Interhelical reactions G protein-coupled receptor rhodopsin and, 860-63
- Interleukin 1 (IL-1) stress-activated cytokines and the heart, 81-95
- Interleukin 6 (IL-6) lung gene therapy and, 602
- Intrabacterial disease gastric biology of *Helicobacter pylori* and, 354-59
- Ion channels hyperpolarization-activated cation currents and, 453-72 macula densa cell signaling and, 481-95 transducing touch in *Caenorhabditis elegans* and, 429-46
- Ion selectivity calcium channel permeation and selectivity, 133-55
- Ion transport alveolar type I epithelial cells and, 669, 683-84 calcium channel permeation and selectivity, 146-47
- Ionomycin acid secretion by parietal cell and, 121
- IRAK protein second messenger pathways in pulmonary host defense and, 646, 656
- $\beta$ IRKO mice insulin receptor knockout mice and, 322
- Isoelectric point gastric biology of *Helicobacter pylori* and, 349, 354, 363
- ITR promoter lung gene therapy and, 598-99
- ## J
- Juxtaglomerular apparatus macula densa cell signaling and, 491-93 paracrine factors in tubuloglomerular response and, 501-20
- ## K
- K<sup>+</sup> calcium channel permeation and selectivity, 133-55 gastric enterochromaffin-like cells and, 371, 373-74 macula densa cell signaling and, 481-95 Na,K-ATPase structure and mechanism, 817-41
- Ketoacidosis insulin receptor knockout mice and, 313, 319, 323-25



- Kidneys**  
 hensin and terminal  
 differentiation, 567–80  
 liporegulation and, 338  
 macula densa cell signaling  
 and, 481–95  
 mammalian urea  
 transporters and, 543–58  
 paracrine factors in  
 tubuloglomerular  
 response and, 501–20  
 type IIa Na/Pi  
 cotransporter and, 531–36
- Kinesin movement**  
 processive and  
 nonprocessive models of  
 conclusions, 172  
 directionality, 163  
 introduction, 161  
 nonprocessive  
 mechanisms, 170–72  
 processive mechanisms,  
 163–65, 167–70  
 properties of kinesin  
 motility, 163–65  
 structure of kinsein,  
 165–67
- Kinetics**  
 Na,K-ATPase structure and  
 mechanism, 819  
 TRP channel regulation via  
 lipid second messengers  
 and, 735, 745–47
- Kir gene**  
 TRP channel regulation via  
 lipid second messengers  
 and, 744
- KL-4 surfactant**  
 surfactant therapy for  
 ALI/ARDS and, 619, 625
- Knockouts**  
 gastric acid secretion in  
 genetically engineered  
 mice and, 383–96  
 insulin receptor knockout  
 mice and, 313  
 paracrine factors in  
 tubuloglomerular  
 response and, 501, 505–6,  
 514–15
- L**
- L-165041**  
 nuclear receptors in  
 metabolism and, 264
- Lactate**  
 NMR of glutamate  
 neurotransmitter flux and  
 neuroenergetics, 411–13
- LacZ reporter gene**  
 lung gene therapy and, 599
- Laminin**  
 hensin and terminal  
 differentiation, 571
- LAMP proteins**  
 aminophospholipid  
 asymmetry and, 717
- Large aggregates**  
 surfactant therapy for  
 ALI/ARDS and, 616–19
- Lattice**  
 crystallographic  
 G protein-coupled  
 receptor rhodopsin and,  
 857–58
- Leakiness**  
 membrane  
 mitochondrial variation in  
 vertebrate muscle and,  
 179–81
- Lecithin: cholesterol  
 acyltransferase (LCAT)**  
 nuclear receptors in  
 metabolism and, 262
- Lectins**  
 alveolar type I epithelial  
 cells and, 671, 683, 687
- Left ventricular remodeling**  
 stress-activated cytokines  
 and the heart, 93–94
- Length constants**  
 hyperpolarization-activated  
 cation currents and,  
 453–72
- Lentiviruses**  
 recombinant  
 lung gene therapy and,  
 592
- Leptin**  
 insulin receptor knockout  
 mice and, 321  
 liporegulation and, 333  
 nuclear receptors in  
 metabolism and, 269, 271
- Leukemia**  
 aminophospholipid  
 asymmetry and, 710
- Ligands**  
 aminophospholipid  
 asymmetry and, 701,  
 711–18  
 nuclear receptors in  
 metabolism and, 261,  
 263–68
- Light-sensitive chromophore**  
 G protein-coupled receptor  
 rhodopsin and, 851–71
- Limulus spp.**  
 TRP channel regulation via  
 lipid second messengers  
 and, 739
- Linkage analysis**  
 functional genomics and  
 comparative physiology  
 of hypoxia, 208
- Lipid bilayer**  
 phosphoinositide  
 regulation of actin  
 cytoskeleton and, 761,  
 779–80
- Lipid receptors**  
 aminophospholipid  
 asymmetry and, 701–20  
 cardiovascular  
 development and  
 angiogenesis, 26–29  
 cell migration, 27–28  
 EDG receptors, 28–37  
 embryonic development,  
 29–37  
 future research, 37–38



- introduction, 23-26  
*lpa*<sub>1</sub>, 35-36  
 mouse, 31-37  
 platelet-derived growth factor, 34-35  
*slp*<sub>1</sub>, 32-35  
*slp*<sub>2</sub>, 29-32  
*slp*<sub>3</sub>, 36-37  
 signaling, 27-28  
 summary, 37-38  
 vascular maturation, 28-29  
 zebrafish, 29-31
- phosphoinositide  
 regulation of actin  
 cytoskeleton and, 761-80
- phosphoinositides in  
 membrane retrieval and  
 insertion, 791-808
- TRP channel regulation via  
 lipid second messengers  
 and, 735-52
- Lipids  
 cardiac hypertrophy and,  
 60-62  
 decade of, 697-99  
 gastric biology of  
*Helicobacter pylori* and,  
 353, 359  
 insulin receptor knockout  
 mice and, 313-25  
 nuclear receptors in  
 metabolism and, 261,  
 268, 280-84  
 second messenger  
 pathways in pulmonary  
 host defense and, 642-57  
 surfactant therapy for  
 ALI/ARDS and, 615, 616,  
 618, 620, 625, 628, 632
- Lipopenia  
 liporegulation and, 343
- Lipopolysaccharide (LPS)  
 gastric biology of  
*Helicobacter pylori* and,  
 353  
 second messenger  
 pathways in pulmonary  
 host defense and, 642-57
- Lipoprotein lipase  
 nuclear receptors in  
 metabolism and, 262,  
 269, 274-76
- Liporegulation  
 fat tolerance, 335-41  
 introduction, 333-34  
 leptin, 334-41  
 leptin deficiency, 335-41  
 lipoapoptosis, 340, 342-44  
 lipotoxicity, 340, 342-44  
 post-receptor leptin  
 resistance in diet-induced  
 obesity, 343
- Liposomes  
 lung gene therapy and,  
 592-93, 597
- Lipotoxicity  
 liporegulation and, 333,  
 340, 342-44
- LIRKO mice  
 insulin receptor knockout  
 mice and, 321
- Lithium  
 mammalian urea  
 transporters and, 551, 557
- Lithocholic acid  
 nuclear receptors in  
 metabolism and, 262
- Liver  
 insulin receptor knockout  
 mice and, 318-19, 321,  
 325  
 liporegulation and, 335,  
 337-38, 340  
 mammalian urea  
 transporters and, 543,  
 556-58  
 nuclear receptors in  
 metabolism and, 282-84
- Liver receptor homolog-1  
 (LRH-1)  
 nuclear receptors in  
 metabolism and, 261-62,  
 267-68
- Liver X receptor (LXR)  
 nuclear receptors in  
 metabolism and, 261-62,  
 265-66, 268, 273,  
 276-77, 279
- Localization  
 phosphoinositides in  
 membrane retrieval and  
 insertion, 798-800, 804-5
- Long-term regulation  
 mammalian urea  
 transporters and, 549-52,  
 554-55
- Loss-of-function mutants  
 gastric acid secretion in  
 genetically engineered  
 mice and, 387-88
- lov-1* mutant  
 transducing touch in  
*Caenorhabditis elegans*  
 and, 443-44
- Low-density lipoprotein  
 (LDL)  
 nuclear receptors in  
 metabolism and, 262
- LOX-1 receptor  
 aminophospholipid  
 asymmetry and, 712, 717
- lpa*<sub>1</sub> gene  
 lipid receptors in  
 cardiovascular  
 development and, 35-36,  
 38
- L-type calcium channels  
 gastric  
 enterochromaffin-like  
 cells and, 371, 373-74
- Lucilia* spp.  
 TRP channel regulation via  
 lipid second messengers  
 and, 739
- Lungs  
 alveolar type I epithelial  
 cells and, 669-88  
 gene therapy for inherited  
 diseases of, 585-604  
 second messenger

- pathways in pulmonary  
host defense and, 642–57  
surfactant therapy for  
ALI/ARDS and, 613–32
- LXR genes**  
nuclear receptors in  
metabolism and, 265–66
- Lycopersicon esculentum*  
alveolar type I epithelial  
cells and, 683
- Lymnaea stagnalis*  
transducing touch in  
*Caenorhabditis elegans*  
and, 441
- Lysophosphatidic acid  
lipid receptors in  
cardiovascular  
development and, 23–38
- Lysophospholipids  
lipid receptors in  
cardiovascular  
development and, 23–38
- M**
- Maclura pomifera*  
alveolar type I epithelial  
cells and, 671
- $\alpha$ 2-Macroglobulin receptor  
aminophospholipid  
asymmetry and, 712
- Macrophages  
alveolar type I epithelial  
cells and, 669  
aminophospholipid  
asymmetry and, 703,  
711–13  
second messenger  
pathways in pulmonary  
host defense and, 642–57
- Macrosialin  
aminophospholipid  
asymmetry and, 712
- Macula densa cells  
paracrine factors in  
tubuloglomerular  
response and, 501, 510  
signaling and  
adenosine, 493–95  
apical K conductance,  
485–86  
ATP, 493–95  
cytosolic calcium  
regulation, 489–90  
introduction, 481–83  
juxtaglomerular  
apparatus, 491–93  
membrane potential,  
483–91  
multi-photon imaging,  
491–93  
Na/H exchangers,  
486–88  
Na:K:Cl cotransport,  
483–91  
signaling, 493–95  
sodium regulation,  
488–89  
transport, 490–91
- $^{13}\text{C}$  Magnetic resonance  
spectroscopy ( $^{13}\text{C}$  MRS)  
glutamate neurotransmitter  
flux and neuroenergetics,  
401–20
- Maladaptation  
cardiac hypertrophy and,  
64–66  
stress-activated cytokines  
and the heart, 81, 88–94
- Maloney murine leukemia  
virus (MLV)  
lung gene therapy and,  
592
- Malonyl CoA  
liporegulation and, 335
- Mammals  
urea transporters and,  
543–58
- Manduca* spp.  
transducing touch in  
*Caenorhabditis elegans*  
and, 437
- Mast cells  
aminophospholipid  
asymmetry and, 703
- Master regulators  
nuclear receptors in  
metabolism and, 261
- Matrix metalloproteinases  
(MMPs)  
cardiac hypertrophy and,  
62–63
- Maxi-anion channel  
macula densa cell signaling  
and, 481–95
- MDR proteins  
aminophospholipid  
asymmetry and, 705–6
- mec* genes  
transducing touch in  
*Caenorhabditis elegans*  
and, 429, 434–35,  
438–40, 442
- Mechanosensation  
transducing touch in  
*Caenorhabditis elegans*  
and, 429–46
- MEF2 protein  
cardiac hypertrophy and,  
52–53
- Megakaryocytes  
aminophospholipid  
asymmetry and, 703
- Melanoma  
aminophospholipid  
asymmetry and, 703, 710
- Membrane biogenesis  
mitochondrial variation in  
vertebrate muscle and,  
184–85
- Membrane domains  
Na,K-ATPase structure and  
mechanism, 838–40
- Membrane fission  
phosphoinositides in  
membrane retrieval and  
insertion, 791–808
- Membrane fusion  
acid secretion by parietal  
cell and, 103–23
- Membrane insertion/retrieval  
phosphoinositides in

- membrane retrieval and insertion, 791–808
- Membrane leakiness  
mitochondrial variation in vertebrate muscle and, 179–81
- Membrane lipid asymmetry  
apoptosis and, 701–20
- Membrane potential  
macula densa cell signaling and, 483–91
- Membrane protein structure  
Na,K-ATPase structure and mechanism, 817–41
- Membrane protrusions  
phosphoinositides in membrane retrieval and insertion, 798–800
- Membrane recruitment  
acid secretion by parietal cell and, 103–23
- Membrane transport  
type IIa Na/Pi cotransporter and, 531–36
- Mer receptor  
aminophospholipid asymmetry and, 712–73
- Metabolic receptors  
nuclear receptors in metabolism and, 261
- Metabolic stress  
TRP channel regulation via lipid second messengers and, 745
- Metabolic syndrome  
liporegulation and, 333, 338  
nuclear receptors in metabolism and, 269
- Metabolism  
alveolar type I epithelial cells and, 669  
cardiac hypertrophy and, 60–62  
cholesterol and, 7–8  
insulin receptor knockout mice and, 313–25  
liporegulation and, 341, 343  
mitochondrial variation in vertebrate muscle and, 178–83, 190–92  
TRP channel regulation via lipid second messengers and, 748
- Methylation  
alveolar type I epithelial cells and, 673
- N*-Methyl-D-glucamine  
mammalian urea transporters and, 555–56
- Metronidazole  
gastric biology of *Helicobacter pylori* and, 349, 364
- Mg<sup>2+</sup>  
Na,K-ATPase structure and mechanism, 817–41
- Mg<sup>2+</sup>-ATPase  
aminophospholipid asymmetry and, 704–5
- MgE<sub>1</sub>-P[3Na] complex  
Na,K-ATPase structure and mechanism, 837
- Microarray technology  
applications in environmental and comparative physiology  
biological regulation, 232–34  
cDNA clone sets as core requirement for expression analysis of nonmodel species, 238–41  
environmental stress responses in nonmodel organisms, 246–47  
evolutionary analysis, 243–44  
expression analysis, 238–41  
genetic analysis, 243–44  
genomes, 249–50  
introduction, 231–32  
model organisms and their responses to the natural environment, 244–46  
new arrayed paradigm, 234–38  
perspectives, 250–51  
sources of variability in expression profiles, 240–41  
species, 247–49  
taxa, 247–49  
transcriptome, 232–49  
utility of microarray approaches, 242–43
- Microtubules  
processive and nonprocessive models of kinesin movement, 161–72
- Microvilli  
hensin and terminal differentiation, 567–80  
TRP channel regulation via lipid second messengers and, 745–46
- mil* mutant  
lipid receptors in cardiovascular development and, 29–32
- MIRKO mice  
insulin receptor knockout mice and, 318–19
- Mitochondrial variation  
in vertebrate muscle  
adaptive remodeling, 187–89  
development, 187–89  
differentiation, 187–89  
energy metabolism, 178–83  
evolutionary variation, 181–83, 192–93  
gene expression, 189–90

- introduction, 177–78
- membrane biogenesis, 184–85
- membrane leakiness, 179–81
- mitochondrial capacity, 187–93
- organelle structure, 183–87
- oxidative phosphorylation, 178–83
- phenotypic variation, 181–83
- reactive oxygen species, 179–81
- regulation, 183–93
- reticulum, 186–87
- thermogenesis, 179–81
- ultrastructural analysis, 183–84
- Mitogen-activated protein kinases (MAPKs)
  - cardiac hypertrophy and, 57–58
  - second messenger pathways in pulmonary host defense and, 642–57
- Mitoxantrone-resistance protein (MRP)
  - aminophospholipid asymmetry and, 705
- Moesin
  - phosphoinositide regulation of actin cytoskeleton and, 777
- Molecular motors
  - processive and nonprocessive models of kinesin movement, 161–72
- Molecular phenotype
  - alveolar type I epithelial cells and, 669
- monoamine oxidase A* gene
  - functional genomics and comparative physiology of hypoxia, 206
- Motor domains
  - processive and nonprocessive models of kinesin movement, 161–72
- Mucosal hypertrophy
  - gastric acid secretion in genetically engineered mice and, 390–91
- Multi-ion pore
  - calcium channel permeation and selectivity, 136–37
- Multi-photon imaging
  - macula densa cell signaling and, 481, 491–93
- Multidrug resistance proteins
  - aminophospholipid asymmetry and, 705–6
- Mus musculus*
  - functional genomics and comparative physiology of hypoxia, 207
  - microarray technology and, 232
- Musca* spp.
  - TRP channel regulation via lipid second messengers and, 739
- Muscle
  - hyperpolarization-activated cation currents and, 453–72
  - insulin receptor knockout mice and, 318–20
  - liporegulation and, 335, 338
  - mitochondrial variation and, 177–93
  - nuclear receptors in metabolism and, 270–73
- Mutagenesis
  - gastric acid secretion in genetically engineered mice and, 383–96
  - gastric biology of *Helicobacter pylori* and, 349, 360–62
- G protein-coupled receptor
  - rhodopsin and, 856–63
- Na,K-ATPase structure and mechanism, 817–41
- Mycobacterium* spp.
  - microarray technology and, 250
- MyD88 protein
  - second messenger pathways in pulmonary host defense and, 646, 656
- Myocardium
  - aminophospholipid asymmetry and, 703
  - cardiac hypertrophy and, 45–66
  - stress-activated cytokines and the heart, 81–95
- Myosin Vb
  - acid secretion by parietal cell and, 116–17
- N
- Na<sup>+</sup>
  - calcium channel permeation and selectivity, 133–55
  - macula densa cell signaling and, 488–89
  - Na,K-ATPase structure and mechanism, 817–41
- NaCl
  - macula densa cell signaling and, 481–95
  - paracrine factors in tubuloglomerular response and, 501, 516–17
- Na/H exchangers
  - cardiac hypertrophy and, 63–64
  - macula densa cell signaling and, 486–88
  - Na,K-ATPase  $\alpha$ -subunit, 825–26

- $\alpha\gamma$ - $\beta\gamma$  subunit interactions, 827, 829  
 A domain, 824, 832–38  
 ATP binding, 835–36  
 ATP-binding site, 821–22  
 ATP-driven  $K^+$  uptake, 838–39  
 Ca-ATPase, 820–25  
 catalytic cycle, 832–35  
 cation specificity, 831–32  
 conclusions, 841  
 cytoplasmic domain, 832–37  
 cytoplasmic domains, 838–40  
 E<sub>1</sub>-E<sub>2</sub> conformations, 835  
 E<sub>1</sub>-E<sub>2</sub> transitions, 820–40  
 energy transduction, 832–40  
 helix packing stability, 825–28  
 introduction, 817–19  
 K<sup>+</sup>-activated  
   dephosphorylation, 840  
 K<sup>+</sup> binding sites, 828, 830–32  
 kinetic mechanism, 819  
 membrane domains, 838–40  
 Mg<sup>2+</sup> binding, 837  
 MgATP, 835–36  
 MgE<sub>1</sub>-P[3Na] complex, 837  
 Na<sup>+</sup> binding sites, 828, 830–32  
 Na<sup>+</sup>-dependent  
   phosphorylation, 840  
 Na<sup>+</sup> movements, 839–40  
 N domain, 820–38  
 P domain, 823–24, 832–40  
 perspectives, 841  
 phosphorylation, 840  
 structure, 820–25  
 transmembrane region, 824–25, 828, 830–32  
 Na:K:2Cl  
   macula densa cell signaling  
     and, 481, 483–91  
   Na/Pi cotransporter type IIa (NaPi-IIa)  
     regulation in proximal tubule  
       conclusions, 536  
       overview, 531–32  
       PDZ/NaPi-IIa network, 534–36  
       protein interactions, 534–36  
       regulatory mechanisms, 532–33  
 Natural selection  
   functional genomics and comparative physiology of hypoxia, 222–23  
 N cytoplasmic domains  
   Na,K-ATPase structure and mechanism, 817, 820–21, 832–38  
 Nestin-positive neurons  
   insulin receptor knockout mice and, 322–23  
 Neural pathways  
   acid secretion by parietal cell and, 103–23  
 Neuronal automaticity  
   hyperpolarization-activated cation currents and, 468–69  
 Neurons  
   aminophospholipid asymmetry and, 703, 706–7  
   hyperpolarization-activated cation currents and, 453–72  
   insulin receptor knockout mice and, 322, 323  
   NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
   paracrine factors in tubuloglomerular response and, 501–20  
   transducing touch in *Caenorhabditis elegans* and, 434–35, 440, 442, 445  
 Neuropeptide Y (NPY)  
   insulin receptor knockout mice and, 323  
 Neurophysiology  
   hyperpolarization-activated cation currents and, 453–72  
   NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
   transducing touch in *Caenorhabditis elegans* and, 429–46  
 Neurotransmitters  
   gastric  
     enterochromaffin-like cells and, 371–77  
   NMR of glutamate neurotransmitter flux and neuroenergetics, 401–20  
 New arrayed paradigm  
   microarray technology and, 234–38  
 NF- $\kappa$ B  
   second messenger pathways in pulmonary host defense and, 642–57  
 NFAT proteins  
   cardiac hypertrophy and, 46–49  
 Ni<sup>2+</sup>  
   gastric biology of *Helicobacter pylori* and, 349, 355, 364  
 NIDDM1 mutant  
   insulin receptor knockout mice and, 324  
*ninaE* gene  
   TRP channel regulation via lipid second messengers and, 739  
 Nitric oxide (NO)  
   paracrine factors in tubuloglomerular

- response and, 501, 514–20
- Nitric oxide synthase (NOS)  
paracrine factors in tubuloglomerular response and, 501, 514–15
- nompC* mutant  
transducing touch in *Caenorhabditis elegans* and, 442–43
- Non-oxidative glycolysis  
NMR of glutamate neurotransmitter flux and neuroenergetics, 411
- Nonprocessive motors  
kinesin movement and, 161–72
- Non-selectivity filter domains  
calcium channel permeation and selectivity, 146
- norpA* gene  
TRP channel regulation via lipid second messengers and, 739, 741–42, 745–46
- NOS-1 knockout mice  
paracrine factors in tubuloglomerular response and, 514–15
- NOS-3* gene  
functional genomics and comparative physiology of hypoxia, 206
- NR0B2  
nuclear receptors in metabolism and, 268
- NR5A2  
nuclear receptors in metabolism and, 267
- NRF transcription factor  
mitochondrial variation in vertebrate muscle and, 177, 189
- NRH* genes  
nuclear receptors in metabolism and, 265, 266
- <sup>13</sup>C Nuclear magnetic resonance (<sup>13</sup>C NMR)  
glutamate neurotransmitter flux and neuroenergetics, 401–20
- Nuclear receptors  
in control of metabolism  
ABCA1, 275–77  
adipocytes, 269–73  
apo-AI, 275  
apo-AII, 275  
bile acids, 280–86  
cholesterol, 280–84  
coactivators, 263  
conclusions, 287–88  
corepressors, 263  
detoxification, 284–87  
differentiation of adipocytes, 269–70  
dimerization, 262–63  
drug-drug interactions, 286–87  
endobiotics, 284–87  
energy homeostasis, 271–72  
enterohepatic circulation, 282–84  
fat, 270–73  
FXR, 266  
general concepts, 262  
glucose homeostasis, 270–73  
glucose sensitivity, 269–73  
HDL, 273–80  
intestinal lipid metabolism, 280–84  
ligands, 263–68  
LRH-1, 267  
LXR $\alpha$  and  $\beta$ , 265–66  
metabolic sensors in health and disease, 268–87  
muscle, 270–73  
NR0B2, 268  
NR1H2, 265–66  
NR1H3, 265–66
- NR1H4, 266  
NR1I2, 266–67  
NR5A2, 267  
pancreas, 270–73  
parallel reverse cholesterol transport pathway, 279–80  
PPAR $\alpha$ , 264–75  
PPAR $\beta/\delta$ , 264  
PPAR $\gamma$ , 264–73  
PPARs, 263–75  
PXR, 266–67  
PXR/SXR, 284–87  
reverse cholesterol transport, 273–80  
SHP, 268  
structure, 262–63  
tissue distribution, 263–68  
triglycerides, 273–80  
xenobiotics, 284–87
- 5'-Nucleotidase  
paracrine factors in tubuloglomerular response and, 501–20
- O**
- Obesity  
insulin receptor knockout mice and, 319, 323  
liporegulation and, 333–44  
nuclear receptors in metabolism and, 261, 268, 271
- OLQ neurons  
transducing touch in *Caenorhabditis elegans* and, 435
- Onchorhynchus mykiss*  
functional genomics and comparative physiology of hypoxia, 217
- "One-bond-flip" mechanism  
G protein-coupled receptor rhodopsin and, 855
- Opsin  
G protein-coupled receptor

- rhodopsin and, 851–71
- ORCC epithelial ion channel  
lung gene therapy and,  
593
- Orexin  
insulin receptor knockout  
mice and, 323
- Organic anion transporting  
polypeptide (OATP)  
nuclear receptors in  
metabolism and, 262,  
282, 285–86
- Organogenesis  
lipid receptors in  
cardiovascular  
development and, 23–38
- osm-9* mutant  
transducing touch in  
*Caenorhabditis elegans*  
and, 429, 443–44
- Ouabain  
mammalian urea  
transporters and, 555–56
- Outer membrane leaflet  
aminophospholipid  
asymmetry and, 701–20
- Ovarian cancer  
aminophospholipid  
asymmetry and, 710
- Oxidative cleavage  
Na,K-ATPase structure and  
mechanism, 817–41
- Oxidative glycolysis  
NMR of glutamate  
neurotransmitter flux and  
neuroenergetics, 401–20
- Oxidative phosphorylation  
mitochondrial variation in  
vertebrate muscle and,  
177–83
- Oxygen  
functional genomics and  
comparative physiology  
of hypoxia, 203–24  
NMR of glutamate  
neurotransmitter flux and  
neuroenergetics, 401–20
- P**
- P1 purinergic agonists  
paracrine factors in  
tubuloglomerular  
response and, 501–7
- Pacemaker  
hyperpolarization-activated  
cation currents and,  
453–72
- Packaging capacity  
lung gene therapy and,  
598–99
- Pancreatic  $\beta$ -cells  
insulin receptor knockout  
mice and, 313–25  
liporegulation and, 338,  
340–43  
nuclear receptors in  
metabolism and, 270–73
- Paracrine factors  
tubuloglomerular response  
and, 501–20
- Paracrine pathways  
acid secretion by parietal  
cell and, 103–23
- Parietal cells  
gastric acid secretion in  
genetically engineered  
mice and, 383–96  
gastric biology of  
*Helicobacter pylori* and,  
365
- P cytoplasmic domains  
Na,K-ATPase structure and  
mechanism, 817–41
- PC-12 cells  
aminophospholipid  
asymmetry and, 703
- PDE ciliated sensory neurons  
transducing touch in  
*Caenorhabditis elegans*  
and, 435
- PDZ domains  
TRP channel regulation via  
lipid second messengers  
and, 745–46
- PDZ proteins  
type IIa Na/Pi cotransporter  
and, 531, 534–36
- Pendrin  
hensin and terminal  
differentiation, 569
- Pepck* gene  
insulin receptor knockout  
mice and, 317
- Peptic ulcer disease  
gastric biology of  
*Helicobacter pylori* and,  
349, 351–52
- Perilipin  
nuclear receptors in  
metabolism and, 269
- Periplasm  
bacterial  
gastric biology of  
*Helicobacter pylori*  
and, 349
- Permeation  
calcium channel  
permeation and  
selectivity, 133–55
- Peromyscus maniculatus*  
functional genomics and  
comparative physiology  
of hypoxia, 215–16  
mitochondrial variation in  
vertebrate muscle and,  
189
- Peroxisome  
proliferator-activated  
receptors (PPARs)  
liporegulation and, 335–36  
mitochondrial variation in  
vertebrate muscle and,  
189  
nuclear receptors in  
metabolism and, 261–75
- PGC-1 protein  
liporegulation and, 335  
mitochondrial variation in  
vertebrate muscle and,  
177, 189, 193
- pH  
gastric acid secretion in



- genetically engineered mice and, 383-96
- gastric biology of *Helicobacter pylori* and, 349-65
- Phagocytosis
  - aminophospholipid asymmetry and, 701, 711-13
- PH domain
  - phosphoinositides in membrane retrieval and insertion, 791-95, 797-99, 804, 807
- Phenotype
  - alveolar type I epithelial cells and, 669-88
  - insulin receptor knockout mice and, 323
  - lung gene therapy and, 594, 595
  - mitochondrial variation in vertebrate muscle and, 177, 181-83
- Phloretin
  - mammalian urea transporters and, 546, 549, 554-57
- Phosphate
  - inorganic
    - type IIa Na/Pi cotransporter and, 531-36
- Phosphatidylethanolamine
  - aminophospholipid asymmetry and, 701-20
- Phosphatidyl inositol 4,5 biphosphate (PIP<sub>2</sub>)
  - phosphoinositide regulation of actin cytoskeleton and, 761-80
  - phosphoinositides in membrane retrieval and insertion, 791-808
- TRP channel regulation via lipid second messengers
  - and, 735-52
- Phosphatidylinositol 4,5 triphosphate (PIP<sub>3</sub>)
  - phosphoinositides in membrane retrieval and insertion, 791-808
- Phosphatidylserine
  - aminophospholipid asymmetry and, 701-20
- Phosphoenol pyruvate
  - carboxykinase (PEPCK) nuclear receptors in metabolism and, 269
- Phosphoinositide 3-kinases (PI3Ks)
  - cardiac hypertrophy and, 49-51
  - nuclear receptors in metabolism and, 272
  - second messenger pathways in pulmonary host defense and, 653-54
- Phosphoinositides (PPIs)
  - actin cytoskeleton regulation by
    - $\alpha$ -actinin, 775-76
    - actin nucleation, 771, 773-75
    - activation, 767-68
    - Arf family GTPases, 768
    - Arp2/3, 771-73
    - capping, 774-75
    - cofilin/ADF, 773-74
    - deletion of PIP5KI genes, 770
    - deletion of PPI 5-phosphatase genes, 769-70
    - dendritic actin nucleation, 771
    - experimental manipulation, 768-70
    - explosive proliferation of known PPI-binding proteins and PPI-binding modules, 762-64
- ezrin/radixin/moesin, 777
- filamin, 776-77
- gelsolin, 774-75
- genetics, 769-70
- historical overview, 761-62
- mechanisms for PPI regulation of actin-binding proteins, 778-79
- overexpression, 769
- PIP<sub>2</sub>, 766-75
- PIP<sub>3</sub>, 766
- PIP5KI, 767-70
- plasma membrane, 767-68
- PPI 5-phosphatase, 769-70
- PPI-binding motifs in cytoskeletal proteins, 763-64
- PPI transients at site of dynamic actin polymerization, 764-68
- protein binding effects on lipid bilayer and PPI binding on protein structures, 779-80
- recruitment, 767-68
- Rho family GTPases, 767
- severing, 773-75
- spatial and temporal regulation of PPI at sites of actin assembly, 765-67
- specificity of electrostatic interactions, 764
- structural conservation, 762-63
- synergistic activation, 772
- talín, 777-78
- vinculin, 777-78



- WASP family proteins, 771-73
- in membrane retrieval and insertion
- asymmetric cellular localization, 792-97
- asymmetric localization of PtdIns(4,5)P2 in plasma membrane, 804-5
- conclusions, 807-8
- detection of PPIs in intact cells, 793-95
- dynamics of PtdIns(3,4,5)P2
- turnover and function at plasma membrane, 803-7
- dynamics of PtdIns(3,4,5)P3
- turnover and function at plasma membrane, 798-803
- exocytosis and PtdIns(4,5)P2 function, 806-7
- exocytosis at sites of concentrated PtdIns(3,4,5)P3, 800-2
- introduction, 791-92
- localization of PtdIns(3,4,5) in membrane protrusions, 798-800
- membrane recycling pathway, 795-97
- potential mechanisms of PtdIns(3,4,5)P3-mediated exocytosis, 802-3
- PtdIns(4,5)P2 turnover and scission step in membrane retrieval, 805-6
- TRP channel regulation via lipid second messengers and, 747-48
- Phospholipase C
- TRP channel regulation via lipid second messengers and, 735-52
- Phospholipids
- aminophospholipid asymmetry and, 701-20
- gastric biology of *Helicobacter pylori* and, 353, 359
- insulin receptor knockout mice and, 320, 322, 324-25
- lipid receptors in cardiovascular development and, 23-38
- surfactant therapy for ALI/ARDS and, 616, 618, 620, 625, 628, 632
- Phospholipid transfer protein (PLTP)
- nuclear receptors in metabolism and, 262, 278
- Phosphorylation
- acid secretion by parietal cell and, 106-9
- hensin and terminal differentiation, 579
- insulin receptor knockout mice and, 315
- liporegulation and, 335, 341, 343
- mammalian urea transporters and, 543, 548-49
- mitochondrial variation in vertebrate muscle and, 177-83
- Na,K-ATPase structure and mechanism, 840
- second messenger pathways in pulmonary host defense and, 654
- Photobleaching pathway
- G protein-coupled receptor rhodopsin and, 855-56
- Photoreceptors
- TRP channel regulation via lipid second messengers and, 737-45
- Phototransduction
- G protein-coupled receptor rhodopsin and, 851-71
- TRP channel regulation via lipid second messengers and, 735-52
- Phylogeny
- functional genomics and comparative physiology of hypoxia, 203-24
- microarray technology and, 231-51
- Physiological ecology
- functional genomics and comparative physiology of hypoxia, 215-16
- Physiological profiling
- functional genomics and comparative physiology of hypoxia, 211-12
- Ping-pong transport mechanism
- Na,K-ATPase structure and mechanism, 819
- Pituitary adenyl cyclase-activating peptide (PACAP)
- gastric enterochromaffin-like cells and, 371-74
- pkd-2* gene
- transducing touch in *Caenorhabditis elegans* and, 444
- Plants
- processive and nonprocessive models of kinesin movement, 161-72
- Plasma membrane
- acid secretion by parietal cell and, 103-23
- aminophospholipid asymmetry and, 701-20

- gastric  
enterochromaffin-like  
cells and, 371  
phosphoinositide  
regulation of actin  
cytoskeleton and, 761–80  
phosphoinositides in  
membrane retrieval and  
insertion, 791–808
- Plasticity  
hensin and terminal  
differentiation, 576–77
- Platelet-derived growth factor  
(PDGF)  
lipid receptors in  
cardiovascular  
development and, 34–35
- Platelets  
aminophospholipid  
asymmetry and, 703
- Pneumonia  
surfactant therapy for  
ALI/ARDS and, 613–14,  
630
- Pol* gene  
lung gene therapy and, 589,  
592
- Polarity  
hensin and terminal  
differentiation, 567–80  
lung gene therapy and,  
597–98
- Polyclonal antibodies  
mammalian urea  
transporters and, 543
- Polymerization  
hensin and terminal  
differentiation, 567–80  
phosphoinositide  
regulation of actin  
cytoskeleton and, 761,  
764–75
- Polyunsaturated fatty acids  
(PUFAs)  
TRP channel regulation via  
lipid second messengers  
and, 735, 741, 750
- Pores  
multi-ion  
calcium channel  
permeation and  
selectivity, 136–37
- Positive-end expiratory  
pressure (PEEP)  
surfactant therapy for  
ALI/ARDS and, 628,  
630–31
- Positron emission  
tomography (PET)  
NMR of glutamate  
neurotransmitter flux  
and neuroenergetics,  
401–20
- PPAR transcription factor  
mitochondrial variation in  
vertebrate muscle and,  
177–93
- ppk* gene  
transducing touch in  
*Caenorhabditis elegans*  
and, 437
- Predicted structures  
calcium channel  
permeation and  
selectivity, 152–54
- Pregnane X receptor/steroid  
and xenobiotic receptor  
(PXR/SXR)  
nuclear receptors in  
metabolism and, 261–62,  
266–67, 284–87
- Pre-therapeutic mRNA  
(PTM)  
lung gene therapy and,  
600–1
- Primary pacemaking  
hyperpolarization-activated  
cation currents and,  
468–69
- Procambarus alleni*  
transducing touch in  
*Caenorhabditis elegans*  
and, 433
- Processive motors  
kinesin movement and,  
161–72
- Promoter specificity  
alveolar type I epithelial  
cells and, 673–74
- Prostatic hyperplasia  
history of research, 1,  
14–16
- Protein kinase A (PKA)  
acid secretion by parietal  
cell and, 106–9
- Protein kinase C (PKC)  
cardiac hypertrophy and,  
58–59  
insulin receptor knockout  
mice and, 320
- Protein kinases  
type IIa Na/Pi  
cotransporter and,  
531–36
- Protein sorting  
phosphoinositides in  
membrane retrieval and  
insertion, 791–808
- Proteolytic cleavage  
Na,K-ATPase structure and  
mechanism, 817–41
- Proton motive force  
gastric biology of  
*Helicobacter pylori* and,  
349, 354–59
- Proton pump  
acid secretion by parietal  
cell and, 103–23
- Proton pump inhibitors (PPIs)  
gastric biology of  
*Helicobacter pylori* and,  
349, 364–65
- Protostomes  
stress-activated cytokines  
and the heart, 84–85
- Protozoa  
processive and  
nonprocessive models of  
kinesin movement,  
161–72
- Proximal tubule

- type IIa Na/Pi cotransporter and, 531-36
- PS receptor (PSr) aminophospholipid asymmetry and, 712, 718
- Pseudohermaphroditism male history of research, 1
- Pseudomonas aeruginosa* lung gene therapy and, 587
- PSOX receptor aminophospholipid asymmetry and, 712, 717-18
- P-type cation pumps Na,K-ATPase structure and mechanism, 817-41
- Pulmonary disorders lung gene therapy and, 585-604
- Pulmonary host defense second messenger pathways and, 642
- Pulmonary injury surfactant therapy for ALI/ARDS and, 613-32
- Purinergic receptors paracrine factors in tubuloglomerular response and, 501-7
- Purkinje cells cerebellar hyperpolarization-activated cation currents and, 469
- PX domain phosphoinositides in membrane retrieval and insertion, 791-98, 807
- Q**
- QLQ ciliated sensory neurons transducing touch in *Caenorhabditis elegans* and, 434-35
- R**
- Rab proteins acid secretion by parietal cell and, 114-15
- Radixin phosphoinositide regulation of actin cytoskeleton and, 777
- Raft lipid microdomains phosphoinositide regulation of actin cytoskeleton and, 761
- Rapid regulation mammalian urea transporters and, 548-49
- Rate theory calcium channel permeation and selectivity, 148-51
- rdg* genes TRP channel regulation via lipid second messengers and, 742-44, 747-48
- Reabsorption mammalian urea transporters and, 555-56 type IIa Na/Pi cotransporter and, 531-36
- Reactive oxygen species mitochondrial variation in vertebrate muscle and, 177, 179-81
- Receptor redundancy aminophospholipid asymmetry and, 718-19
- Receptor tyrosine kinases hensin and terminal differentiation, 579 insulin receptor knockout mice and, 322
- Recombinant human deoxyribonuclease (rhDNase) lung gene therapy and, 596-97
- Recycling acid secretion by parietal cell and, 103-23 phosphoinositides in membrane retrieval and insertion, 791, 795-97 TRP channel regulation via lipid second messengers and, 747-48
- Red blood cells (RBCs) aminophospholipid asymmetry and, 703, 706, 709-10 mammalian urea transporters and, 543-58
- Regeneration G protein-coupled receptor rhodopsin and, 855-56
- Regulation alveolar type I epithelial cells and, 672-77, 679-80 gastric acid secretion in genetically engineered mice and, 383-96 macula densa cell signaling and, 481-95 mammalian urea transporters and, 543, 548-52, 554-55 microarray technology and, 232-34 mitochondrial variation in vertebrate muscle and, 183-93 nuclear receptors in metabolism and, 261 paracrine factors in tubuloglomerular response and, 501-20 phosphoinositide regulation of actin cytoskeleton and, 761-80 TRP channel regulation via lipid second messengers and, 735-52 type IIa Na/Pi cotransporter and, 531-36

- Remodeling  
  adaptive  
    mitochondrial variation  
      in vertebrate muscle  
      and, 177, 187-89
- Renal ablation  
  paracrine factors in  
  tubuloglomerular  
  response and, 520
- Renal failure  
  mammalian urea  
  transporters and, 552
- Renal physiology  
  hensin and terminal  
  differentiation, 567-80  
  macula densa cell signaling  
  and, 481-95  
  mammalian urea  
  transporters and, 543-58  
  paracrine factors in  
  tubuloglomerular  
  response and, 501-20  
  type IIa Na/Pi  
  cotransporter and,  
  531-36
- Renin-angiotensin  
  mammalian urea  
  transporters and, 552
- Reproductive abnormalities  
  insulin receptor knockout  
  mice and, 313, 316-17
- Resistin  
  nuclear receptors in  
  metabolism and, 271
- Respiratory genes  
  mitochondrial variation in  
  vertebrate muscle and,  
  177-93
- Response elements  
  nuclear receptors in  
  metabolism and, 262
- Resting potentials  
  hyperpolarization-activated  
  cation currents and, 453,  
  464-65
- Reticulum  
  mitochondrial variation in  
  vertebrate muscle and,  
  177, 186-87
- Retinal photoreceptor protein  
  G protein-coupled receptor  
  rhodopsin and, 851-71
- Retinitis pigmentosa  
  G protein-coupled receptor  
  rhodopsin and, 863
- Retinoid X receptor (RXR)  
  nuclear receptors in  
  metabolism and, 262-66,  
  270, 276-78
- Retroviruses  
  recombinant  
  lung gene therapy and,  
  592
- Reverse cholesterol transport  
  nuclear receptors in  
  metabolism and, 262-80
- Rhodopsin  
  G protein-coupled receptor  
  rhodopsin and, 851-71
- Rho family GTPases  
  phosphoinositide  
  regulation of actin  
  cytoskeleton and, 767
- Ricinus communis*  
  alveolar type I epithelial  
  cells and, 671, 683
- RMD motor neurons  
  transducing touch in  
  *Caenorhabditis elegans*  
  and, 435
- RNA-directed  
  reprogramming  
  lung gene therapy and, 593
- rpk* gene  
  transducing touch in  
  *Caenorhabditis elegans*  
  and, 437
- Ruffles  
  hensin and terminal  
  differentiation, 567-80
- S**
- slp* genes  
  lipid receptors in  
  cardiovascular  
  development and, 29-38
- Saccharomyces cerevisiae*  
  microarray technology and,  
  232, 238, 242, 244-45  
  phosphoinositides in  
  membrane retrieval and  
  insertion, 806
- Salmonella typhimurium*  
  gastric biology of  
  *Helicobacter pylori* and,  
  350  
  phosphoinositides in  
  membrane retrieval and  
  insertion, 806
- Sarcomeric signaling  
  cardiac hypertrophy and,  
  55-57
- Sarcoplasmic reticulum  
  Na,K-ATPase structure and  
  mechanism, 817-41
- Scaffolding  
  phosphoinositide  
  regulation of actin  
  cytoskeleton and, 761-80
- Scavenger receptor  
  superfamily  
  aminophospholipid  
  asymmetry and, 712,  
  716-18  
  paracrine factors in  
  tubuloglomerular  
  response and, 517-18
- Schiff base  
  protonated  
  G protein-coupled  
  receptor rhodopsin and,  
  851-71
- Scission  
  phosphoinositides in  
  membrane retrieval and  
  insertion, 805-6
- Scott syndrome  
  aminophospholipid  
  asymmetry and, 706
- Scramblase  
  aminophospholipid

- asymmetry and, 706
- Seabright Bantam syndrome
  - history of research, 5, 12–13
- Second messengers
  - pathways in pulmonary
    - host defense and conclusions, 657
    - introduction, 642–43
    - LPS, 645–47
    - macrophages, 643–44
    - MAP kinases, 650–53
    - PI 3-kinase pathway, 653–54
    - sepsis, 655–57
    - sphingolipids, 654–55
    - TNF $\alpha$ , 647
    - transcription factors, 647–50
  - phosphoinositide
    - regulation of actin cytoskeleton and, 761–80
  - TRP channel regulation via lipid second messengers and, 735–52
- Segregation analysis
  - functional genomics and comparative physiology of hypoxia, 207–8
- Selective breeding
  - functional genomics and comparative physiology of hypoxia, 207–9, 212–13
- Selectivity
  - calcium channel
    - permeation and selectivity, 133–55
- Self-complementing vectors
  - lung gene therapy and, 599–600
- Sensilla
  - male-specific
    - transducing touch in *Caenorhabditis elegans* and, 435–36
- Sensory mechanotransduction
  - channels
    - transducing touch in *Caenorhabditis elegans* and, 429–46
  - Sensory stimulation
    - NMR of glutamate neurotransmitter flux and neuroenergetics, 416–17
  - Sepsis
    - second messenger
      - pathways in pulmonary
        - host defense and, 642–57
      - surfactant therapy for ALI/ARDS and, 613–14, 624
  - Sequence conservation
    - processive and nonprocessive models of kinesin movement, 161–72
  - Serine palmitoyl transferase
    - liporegulation and, 341–43
  - Serine/threonine kinases
    - insulin receptor knockout mice and, 315
  - Severing
    - phosphoinositide
      - regulation of actin cytoskeleton and, 773–75
  - Sexual differentiation
    - history of research, 1
  - Sickle cells
    - aminophospholipid
      - asymmetry and, 703, 709
  - Signal transduction
    - acid secretion by parietal cell and, 103–23
    - alveolar type I epithelial cells and, 669, 678–81
    - cardiac hypertrophy and, 45–66
    - G protein-coupled receptor
      - rhodopsin and, 851–71
    - hensin and terminal
      - differentiation, 577–78
    - hyperpolarization-activated
      - cation currents and, 464–65
    - insulin receptor knockout mice and, 313–25
    - lipid receptors in cardiovascular
      - development and, 27–28
    - liporegulation and, 340–41, 343
    - lung gene therapy and, 597–98
    - macula densa cell signaling and, 493–95
    - mitochondrial variation in vertebrate muscle and, 177–93
    - nuclear receptors in metabolism and, 261
    - paracrine factors in tubuloglomerular
      - response and, 501–20
    - phosphoinositide
      - regulation of actin cytoskeleton and, 761–80
    - phosphoinositides in membrane retrieval and insertion, 791–808
    - second messenger
      - pathways in pulmonary
        - host defense and, 642–57
    - TRP channel regulation via lipid second messengers and, 735–52
- Sinoatrial node cells
  - hyperpolarization-activated
    - cation currents and, 458
- Site-directed mutagenesis
  - gastric biology of *Helicobacter pylori* and, 349
- Skeletal muscle
  - insulin receptor knockout mice and, 318–20
  - liporegulation and, 335, 338
- Slc14a2* gene
  - mammalian urea

- transporters and, 546–48, 553
- Small aggregates  
surfactant therapy for  
ALI/ARDS and, 616–18
- Small heterodimer partner (SHP)  
nuclear receptors in  
metabolism and, 262, 268, 278–79
- SNAP-25 protein  
gastric  
enterochromaffin-like cells and, 371, 376
- SNARE proteins  
acid secretion by parietal cell and, 103–23  
gastric  
enterochromaffin-like cells and, 371, 376  
hensin and terminal differentiation, 576
- SOCS-3 protein  
liporegulation and, 343
- Sodium taurocholate  
cotransporting  
polypeptide (NTCP)  
nuclear receptors in  
metabolism and, 262, 282
- Somatostatin  
acid secretion by parietal cell and, 112  
gastric acid secretion in  
genetically engineered mice and, 391
- Sp1 elements  
gastric  
enterochromaffin-like cells and, 371, 375
- Spatial regulation  
phosphoinositide  
regulation of actin  
cytoskeleton and, 765–67
- Specificity  
alveolar type I epithelial cells and, 673, 674  
Na,K-ATPase structure and  
mechanism, 831, 832  
phosphoinositide  
regulation of actin  
cytoskeleton and, 764
- Sphingolipids  
second messenger  
pathways in pulmonary  
host defense and, 654–55
- Sphingosine 1-phosphate  
lipid receptors in  
cardiovascular  
development and, 23–38
- Spliceosome-mediated  
*trans*-splicing (SMaRT)  
lung gene therapy and, 600–1
- Spontaneous firing  
hyperpolarization-activated  
cation currents and, 469
- SP proteins  
surfactant therapy for  
ALI/ARDS and, 616–20, 623, 625
- SRA receptors  
aminophospholipid  
asymmetry and, 712, 716
- SRB receptors  
aminophospholipid  
asymmetry and, 712, 716–17
- SRCL receptor  
aminophospholipid  
asymmetry and, 712, 717
- SREC receptor  
aminophospholipid  
asymmetry and, 712, 717
- Staphylococcus aureus*  
acid secretion by parietal cell and, 107
- STAT-3 protein  
cardiac hypertrophy and, 59–60  
liporegulation and, 343
- Stauridiosarsia producta*  
transducing touch in  
*Caenorhabditis elegans*  
and, 433
- Steatosis  
liporegulation and, 333–44
- Stem cell targets  
lung gene therapy and, 595–96
- Steroid 5 $\alpha$ -reductase 2  
deficiency  
history of research, 1, 11–12
- Steroid and xenobiotic  
receptor (SXR)  
nuclear receptors in  
metabolism and, 261–62, 284–87
- Sterol 12 $\alpha$  hydroxylase (CYP8B1)  
nuclear receptors in  
metabolism and, 262, 279–83
- Sterol 27-hydroxylase (CYP27)  
nuclear receptors in  
metabolism and, 262, 279
- Sterol regulatory element  
binding protein (SREBP)  
liporegulation and, 335–36  
nuclear receptors in  
metabolism and, 262, 266
- Stoichiometric coupling  
NMR of glutamate  
neurotransmitter flux and  
neuroenergetics, 401–20
- Stomach  
gastric acid secretion in  
genetically engineered mice and, 383–96  
gastric biology of  
*Helicobacter pylori* and, 349  
gastric  
enterochromaffin-like cells and, 371–77
- Streptococcus salivarius*  
gastric biology of

- Helicobacter pylori* and, 349, 362–63
- Streptozotocin  
mammalian urea transporters and, 552  
nuclear receptors in metabolism and, 265
- Stress  
microarray technology and, 231–51
- Stress-activated cytokines  
heart and  
adaptive effects, 83–88  
conclusions, 94–95  
introduction, 81–82  
left ventricular remodeling, 93–94  
maladaptive effects, 88–94  
myocardial function, 89–93  
overview, 82–83
- Stretch receptors  
transducing touch in *Caenorhabditis elegans* and, 436
- Structural conservation  
phosphoinositide regulation of actin cytoskeleton and, 762–63
- Substituted-cysteine accessibility  
calcium channel permeation and selectivity, 145
- Subthreshold oscillations  
hyperpolarization-activated cation currents and, 469
- Subunit assembly  
hyperpolarization-activated cation currents and, 463–64
- Sulfhydryl reagents  
hensin and terminal differentiation, 572
- Superoxides  
mitochondrial variation in vertebrate muscle and, 177–93
- paracrine factors in tubuloglomerular response and, 501–20
- Surfactant therapy  
for acute lung injury/acute respiratory distress syndrome  
iterations of surfactant in ALI/ARDS, 617–19  
clinical trials, 619–24  
delivery methods, 627–29  
distribution, 627–29  
dosing, 627–29  
exogenous surfactant preparations, 625–32  
future research, 631–32  
introduction, 613–14  
nature of underlying injury, 623–24  
pathophysiology of ALI/ARDS, 614–15  
potential factors affecting outcome in treatment trials, 622–24  
pulmonary surfactant system, 615–19  
summary, 631–32  
surfactant in combination with other therapies, 632  
timing of surfactant administration, 629–30  
ventilation after surfactant administration, 630–31
- Surfaxin  
surfactant therapy for ALI/ARDS and, 619–20, 625
- Survanta  
surfactant therapy for ALI/ARDS and, 620, 625–26
- Synaptic transmission  
hyperpolarization-activated cation currents and, 470–71
- Synaptobrevin  
gastric enterochromaffin-like cells and, 371, 376
- Synaptotagmin  
gastric enterochromaffin-like cells and, 376
- Syndrome X  
nuclear receptors in metabolism and, 269
- Synechocystis* spp.  
microarray technology and, 242
- Synergistic activation  
phosphoinositide regulation of actin cytoskeleton and, 772
- Syntaxin  
gastric enterochromaffin-like cells and, 376  
hensin and terminal differentiation, 576
- Systemic lupus erythematosus (SLE)  
aminophospholipid asymmetry and, 713
- Systems biology  
functional genomics and comparative physiology of hypoxia, 203–24
- T**
- T1 $\alpha$  molecular marker  
alveolar type I epithelial cells and, 671–75
- Talin  
phosphoinositide regulation of actin cytoskeleton and, 777–78
- T cells  
lung gene therapy and, 591
- Temporal regulation



- phosphoinositide regulation of actin cytoskeleton and, 765-67
- Terminal differentiation of intercalated cells
- acid-base balance, 573
  - apical  $\text{Cl}^-:\text{HCO}_3^-$  exchange, 569-70
  - cell culture model of polarity reversal, 570
  - cell types, 567-79
  - collecting tubule, 567
  - conclusions, 579-80
  - cortical collecting tubule, 568-79
  - equivalent of
    - high-density seeding in vivo, 578-79
  - extracellular matrix, 572-73
  - hensin, 570-73
  - origins, 567-79
  - overview, 574-76
  - plasticity of polarity, 576-77
  - signal transduction, 577-78
- Testis
- mammalian urea transporters and, 558
- Testosterone
- history of research, 1, 9-10, 14-16
- Thalamocortical relay neurons
- hyperpolarization-activated cation currents and, 458, 468-69
- Thalassemia
- aminophospholipid asymmetry and, 703, 709
- Thermogenesis
- mitochondrial variation in vertebrate muscle and, 177, 179-81
- Thiazolidinediones
- nuclear receptors in metabolism and, 272
- Thionicotinamide
- mammalian urea transporters and, 557
- Thiourea
- mammalian urea transporters and, 549
- Thrifty gene hypothesis
- liporegulation and, 334
- Thrombospondin
- aminophospholipid asymmetry and, 717
- Time-independent resistance
- gastric biology of *Helicobacter pylori* and, 354
- TIRAP protein
- second messenger pathways in pulmonary host defense and, 646
- Toll-like receptors
- second messenger pathways in pulmonary host defense and, 644-46
- Touch sensation
- transducing touch in *Caenorhabditis elegans* and, 429-46
- Toxicologic receptors
- nuclear receptors in metabolism and, 261
- Trafficking
- acid secretion by parietal cell and, 112-18
  - aminophospholipid asymmetry and, 702, 704
  - phosphoinositides in membrane retrieval and insertion, 791-808
- TRAF protein
- second messenger pathways in pulmonary host defense and, 646
- Transcriptional control
- cardiac hypertrophy and, 52-53
  - gastric enterochromaffin-like cells and, 371
  - microarray technology and, 231-51
  - nuclear receptors in metabolism and, 261
  - second messenger pathways in pulmonary host defense and, 642-57
- Transcription factors
- liporegulation and, 336
  - mitochondrial variation in vertebrate muscle and, 177-93
  - nuclear receptors in metabolism and, 261
  - second messenger pathways in pulmonary host defense and, 647-50
- Transcriptome
- microarray technology and, 232-49
- Transcytosis
- alveolar type I epithelial cells and, 678-81
- Transducing touch in *Caenorhabditis elegans*
- ADE, 435
  - amiloride-sensitive channels, 437-42
  - ASC complexes, 436-37
  - ASH, 434
  - CEP, 435
  - Drosophila* bristles, 442-43
  - force sensitivity, 433-36
  - future research, 444, 446
  - introduction, 429-30
  - male-specific sensilla, 435-36
  - mechanical coupling modes, 431-33
  - miscellaneous cells, 435
  - natural environment, 433-34



- nompC*, 442–43  
 PDE, 435  
 polymodal TRP, 443  
 sexy TRP, 443  
 stretch receptors, 436  
 summary, 444, 446  
 touch cells, 434  
 TRP channels, 442–44  
 Transforming growth factor  $\alpha$  (TGF $\alpha$ )  
   acid secretion by parietal cell and, 111–12  
 Transgenes  
   functional genomics and comparative physiology of hypoxia, 203, 206–7  
   gastric acid secretion in genetically engineered mice and, 383–96  
 Transient receptor potential (TRP) channels  
   regulation of via lipid second messengers  
     amplification, 745–47  
     bump generation model, 746–47  
   Ca<sup>2+</sup> stores, 739–41  
   conclusions, 751–52  
   DAG-activated channels, 749–50  
   DAG kinase mutants, 741–42  
   *Drosophila*  
     phototransduction, 737–38  
     electrophysiology, 737–38  
     excitation mechanism in *Drosophila* photoreceptors, 738–45  
   InsP<sub>3</sub>, 739–41  
   introduction, 735–37  
   kinetics, 745–47  
   lipid messenger of excitation, 741–45  
   mammalian  
     lipid-regulated cation channels, 749–51  
     metabolic stress, 745  
     metabolism, 748  
     microvilli, 745–46  
     PDZ domains, 745–46  
     phosphoinositide turnover, 747–48  
     photoreceptor ultrastructure, 737  
   PIP<sub>2</sub>, 743–44, 747–48, 750–51  
   PUFA-activated channels, 750  
 Transients  
   phosphoinositide regulation of actin cytoskeleton and, 764–68  
 Transition metal-catalyzed oxidative cleavage  
   Na,K-ATPase structure and mechanism, 817–41  
 Translation  
   second messenger pathways in pulmonary host defense and, 642–57  
 Translocases  
   aminophospholipid asymmetry and, 704–5  
 Transmembrane proteins  
   G protein-coupled receptor rhodopsin and, 851–71  
   Na,K-ATPase structure and mechanism, 817–41  
 Transport  
   aminophospholipid asymmetry and, 704–6  
   calcium channel permeation and selectivity, 146–47  
   gastric biology of *Helicobacter pylori* and, 359–62  
   macula densa cell signaling and, 481, 490–91  
   Na,K-ATPase structure and mechanism, 817–41  
   nuclear receptors in metabolism and, 261–62, 272–80  
   *trans*-splicing  
     spliceosome-mediated lung gene therapy and, 600–1  
   Triacylglycerol  
     liporegulation and, 336, 338–40, 342  
   Triglycerides  
     nuclear receptors in metabolism and, 261, 272–80  
 TRP channels  
   transducing touch in *Caenorhabditis elegans* and, 429, 442–44  
   *trp* gene  
     transducing touch in *Caenorhabditis elegans* and, 430  
   TRP channel regulation via lipid second messengers and, 736, 742, 748  
   *trpl* gene  
     TRP channel regulation via lipid second messengers and, 736  
 Tubuloglomerular response  
   macula densa cell signaling and, 481–95  
   paracrine factors and A1AR knockout mice, 505–6  
   adenosine, 502–7, 510–14  
   adenosine clamp, 505–6  
   adenosine receptor blockers, 504–5  
   adenosine receptors, 503–4  
   afferent arterioles, 502–4  
   angiotensin II, 506–7  
   ATP, 508–14  
   autoregulation, 509–10  
   cAMP, 513–14

- diabetes mellitus, 518–20  
ecto-5'-nucleotidase, 513  
extracellular adenosine, 510–14  
introduction, 501–2  
knockouts, 514–15  
luminal NaCl, 516–17  
macula densa cells, 510–11  
nitric oxide, 514–20  
NOS inhibitor studies, 514–15  
NOS-1 knockout mice, 514–15  
NP scavenging, 517–18  
renal ablation, 520  
vasoconstriction, 508–9
- Tumor necrosis factor (TNF)**  
cardiac hypertrophy and, 62–63  
stress-activated cytokines and the heart, 81–95
- Tumor necrosis factor- $\alpha$  (TNF $\alpha$ )**  
nuclear receptors in metabolism and, 262, 269, 271  
second messenger pathways in pulmonary host defense and, 642–57
- Tumors**  
aminophospholipid asymmetry and, 703, 710–11  
hensin and terminal differentiation, 567–80
- Tyrosine kinases**  
hensin and terminal differentiation, 578–79  
insulin receptor knockout mice and, 322
- Tyrosine phosphatases**  
insulin receptor knockout mice and, 315
- U**
- UCP-1 protein**  
insulin receptor knockout mice and, 322
- Ultrastructural analysis**  
mitochondrial variation in vertebrate muscle and, 183–84
- unc mutants**  
transducing touch in *Caenorhabditis elegans* and, 438–42
- Unified model**  
G protein-coupled receptor rhodopsin and, 867–68
- Urea channel**  
gastric biology of *Helicobacter pylori* and, 349, 353, 357–63
- Urea transporters**  
mammalian  
active urea transport, 555–56  
brain, 558  
development, 551, 554  
diabetes mellitus, 552  
extra-renal urea transporters, 558  
glucocorticoids, 551–52  
heart, 557–58  
introduction, 543–58  
kidney, 544–56  
lithium, 551  
liver, 556–57  
long-term regulation, 549–52, 554–55  
rapid regulation, 548–49  
renal failure, 552  
*Slc14a2*, 546–48  
testis, 558  
urea reabsorption, 555–56  
urea secretion, 555  
urine-concentrating ability, 544–45, 548, 551, 554, 556  
UT-A, 545–52, 556–58  
UT-A1, 551  
UT-B, 553–55  
vasopressin, 548–50  
volume expansion, 552
- Urease**  
gastric biology of *Helicobacter pylori* and, 349–50, 353–57, 359, 363–64
- ure genes**  
gastric biology of *Helicobacter pylori* and, 355, 357, 359–65
- UreI protein**  
gastric biology of *Helicobacter pylori* and, 349–50, 362–63
- Urine-concentrating ability**  
mammalian urea transporters and, 543, 545, 548, 551, 554, 556
- Urogenital tract**  
male  
history of research, 1, 12–17
- UT-A proteins**  
mammalian urea transporters and, 543–53, 556–58
- UT-B protein**  
mammalian urea transporters and, 543–55
- V**
- Vascular responses**  
aminophospholipid asymmetry and, 703, 710–11  
lipid receptors in cardiovascular development and, 28–29  
macula densa cell signaling and, 481–95  
paracrine factors in tubuloglomerular response and, 501–20

- Vasoactive intestinal peptide (VIP)  
acid secretion by parietal cell and, 112
- Vasoconstriction  
paracrine factors in tubuloglomerular response and, 501-20
- Vasopressin  
hensin and terminal differentiation, 575  
mammalian urea transporters and, 543, 546, 548-50, 554-56
- Ventilate  
surfactant therapy for ALI/ARDS and, 620-21, 623, 625, 628
- Ventilation  
surfactant therapy for ALI/ARDS and, 630-31
- Vertebrate muscle  
mitochondrial variation in, 177-93
- Very-low-density lipoprotein (VLDL)  
liporegulation and, 340  
nuclear receptors in metabolism and, 262, 274-76
- Vesicular monoamine transporters subtype 2 (VMAT2)  
gastric enterochromaffin-like cells and, 371, 373-75
- Vibrio cholerae*  
gastric biology of *Helicobacter pylori* and, 350
- Vinculin  
phosphoinositide regulation of actin cytoskeleton and, 777-78
- Viruses  
functional genomics and comparative physiology of hypoxia, 216  
lung gene therapy and, 585, 588-604  
surfactant therapy for ALI/ARDS and, 615
- Vision  
G protein-coupled receptor rhodopsin and, 851-71
- Vitamin A  
G protein-coupled receptor rhodopsin and, 851-71
- Vitronectin  
aminophospholipid asymmetry and, 712, 717
- Voltage gating  
calcium channel permeation and selectivity, 133-55  
gastric biology of *Helicobacter pylori* and, 360
- Vomeroglandin  
hensin and terminal differentiation, 571
- W**
- Wall tension  
cardiac hypertrophy and, 45-66
- WASP family proteins  
phosphoinositide regulation of actin cytoskeleton and, 771-73
- Water channel  
alveolar type I epithelial cells and, 669, 675-78
- white gene*  
nuclear receptors in metabolism and, 277
- Whole-genome microarrays  
microarray technology and, 231-51  
Wilson JD, 1-17  
Wound repair  
aminophospholipid asymmetry and, 707-8
- X**
- Xenobiotics  
nuclear receptors in metabolism and, 261, 284-87
- Xenopus laevis*  
gastric biology of *Helicobacter pylori* and, 349, 360, 363  
hensin and terminal differentiation, 569  
mammalian urea transporters and, 545, 553  
transducing touch in *Caenorhabditis elegans* and, 439, 442, 444
- X-ray crystallography  
G protein-coupled receptor rhodopsin and, 851, 857-67
- Y**
- Yeast  
microarray technology and, 232, 238, 242, 244-45  
phosphoinositides in membrane retrieval and insertion, 806
- Yersinia enterocolitica*  
gastric biology of *Helicobacter pylori* and, 350
- Z**
- ZDF *falga* rats  
liporegulation and, 335-41

---

.....

